

# Indiana Neurological Society

## Functional Neurological Disorders: They're Not Fake News

Friday, November 3, 2023  
Wyndham Indianapolis West Hotel

### PROGRAM AGENDA

8:00 AM – 9:20 AM: Registration and Exhibits

9:20 AM – 9:30 AM: Welcome and Introductory Remarks  
**Laurie Gutmann, MD; President, INS; Chair, Dept. of Neurology, Indiana University School of Medicine**

9:30 AM – 10:30 AM: *“Epidemiology, Etiology, and Pathophysiology of Functional Neurological Disorders.”*  
**Mark Hallett, MD; NINDS, NIH**

10:30 AM – 11:30 AM: *“Functional Movement Disorders.”*  
**Sarah Lidstone, MD, PhD; University of Toronto Temerty Faculty of Medicine**

11:30 AM – 1:00 PM: Lunch

11:45 AM – 12:30 PM: INS Business Meeting

11:45 AM – 1:00 PM: Exhibits

1:00 PM – 2:00 PM: *“Persistent Postural-Perceptual Dizziness and Other Functional Vestibular Disorders”*  
**Jeffrey Staab, MD; Mayo Clinic College of Medicine and Science**

2:00 PM – 3:00 PM: *“Advances in Evaluation and Management of Psychogenic Nonepileptic Seizures.”*  
**W. Curt LaFrance, MD, MPH; Brown University Warren Alpert Medical School**

3:00 PM – 3:30 PM: Break and Exhibits

3:30 PM – 4:30 PM: *“Differential Diagnosis and Potential Pitfalls in the Evaluation of Functional Neurological Disorders.”*  
**Sara Finkelstein, MD, MSc; Harvard Medical School**

4:30 PM – 5:30 PM: *“Managing Functional Neurological Disorders in the Emergency Department”*  
**Barbara Dworetzky, MD; Harvard Medical School**

## **Indiana Neurological Society**

### **Functional Neurological Disorders: They're Not Fake News**

**Friday, November 3, 2023**  
**Wyndham Indianapolis West Hotel**

#### **PROGRAM FACULTY**

**Mark Hallett, MD, FAAN**

Distinguished Investigator Emeritus  
National Institute of Neurological Disorders and Stroke  
National Institutes of Health  
Functional Neurological Disorder Society

**Sarah Lidstone, MD, PhD**

Director, Integrated Movement Disorders Program, Toronto Rehabilitation  
Institute, University Health Network  
Assistant Professor of Neurology, University of Toronto

**Jeffrey P Staab, MD, MS**

Chair, Department of Psychiatry and Psychology, Mayo Clinic  
Consultant, Departments of Psychiatry & Psychology & Otorhinolaryngology  
Professor of Psychiatry, Mayo Clinic College of Medicine and Science

**W. Curt LaFrance Jr., MD, MPH, FAAN, FANPA, DFAPA**

Director, Neuropsychiatry and Behavioral Neurology, Rhode Island Hospital  
Director, VA Mind Brain Program, Providence Veterans Affairs Medical Center  
Professor of Psychiatry and Neurology, Brown University Warren Alpert Medical  
School

**Sara A Finkelstein, MD, FRCPC**

Neurologist, Massachusetts General Hospital  
Instructor, Harvard University Medical School

**Barbara A Dworetzky, MD, FAAN**

Chief, Division of Epilepsy & EEG  
Director, Edward B. Bromfield Comprehensive Epilepsy Program  
Brigham and Women's Hospital  
Professor of Neurology, Harvard University Medical School



## 2023 INS FALL MEETING CME INFORMATION



### CME Accreditation

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Indiana State Medical Association through the joint providership of the Indiana Association of Pathologists and the Indiana Neurological Society. The Indiana Association of Pathologists is accredited by the Indiana State Medical Association (ISMA) to provide continuing medical education for physicians.

### Designation Statement

The IAP designates this live activity for 6.0 *AMA PRA Category 1 credits*<sup>™</sup>. Physicians should only claim credit commensurate with their participation in the activity.

### Faculty Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by the Indiana Association of Pathologists (IAP) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an IAP-sponsored activity are required to disclose any relevant financial interest or other relationship with any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients that are discussed in an educational activity. The INS planning committee and those in a position to control the content of this activity have disclosed the relationships displayed in the table on the following page:

### Note

While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

Name of individual	Individual's role in activity	Name of ineligible company	Nature of relationship	Mechanism(s) implemented to mitigate relevant financial relationships
Mark Hallett, MD	Faculty Presenter	<u>VoxNeuro</u> ; <u>QuantalX</u> ; Janssen Pharmaceutical	Consultant	Independent review: no conflict
<u>Sarah Lidstone</u> , MD, PhD	Faculty Presenter	No relationships		
<u>Jeffrey Staab</u> , MD	Faculty Presenter	Sleep Number Corporation	Grant/Research Support as Co- investigator	Independent review. No conflict
W. Curt LaFrance, MD, MPH	Faculty Presenter	No relationships		
Sara Finkelstein, MD, MSc	Faculty Presenter	No relationships		
Barbara <u>Dworetzky</u> , MD	Faculty Presenter	No relationships		
Robert Flint, MD	Planner/ Course Director/Reviewer	No relationships		
Norma Erickson, IAP CME Staff	Reviewer	No relationships		

## **Indiana Neurological Society**

### **Functional Neurological Disorders: They're Not Fake News**

**Friday, November 3, 2023  
Wyndham Indianapolis West Hotel**

#### **PROGRAM OBJECTIVES**

**Title:** “Epidemiology, Etiology, and Pathophysiology of Functional Neurological Disorders.”

1. The participant will be able to discuss the evolution of understanding concerning the underlying mechanism of functional neurologic disorders.
2. The participant will be able to describe the potential causes and risks for the development of functional neurologic disorders.
3. The participant will be able to differentiate between functional and factitious neurologic disorders.

**Title:** “Functional Movement Disorders.”

1. The participant will be able to conduct an appropriate evaluation for functional movement disorders.
2. The participant will be able to communicate the diagnosis for functional movement disorders confidently.
3. The participant will be able to formulate an initial treatment plan for a patient with a functional movement disorder.

**Title:** “Persistent Postural-Perceptual Dizziness and Other Functional Vestibular Disorders”

1. The participant will be able to describe key features of the two currently defined functional vestibular disorders.
2. The participant will be able to initiate an evaluation of a patient with suspected functional dizziness.
3. The participant will be able to develop a management plan for a patient diagnosed with functional dizziness.



**Title:** “Advances in Evaluation and Management of Psychogenic Nonepileptic Seizures.”

1. The participant will be able to list the risk factors for the development of psychogenic nonepileptic seizures.
2. The participant will be able to initiate an appropriate evaluation for psychogenic nonepileptic seizures.
3. The participant will be able to develop a treatment plan for psychogenic nonepileptic seizures.

**Title:** “Differential Diagnosis and Potential Pitfalls in the Evaluation of Functional Neurological Disorders.”

1. The participant will be able to develop a differential diagnosis for functional neurologic disorders.
2. The participant will be able to describe diagnostic pitfalls to be aware of when considering a diagnosis of functional neurologic disorders.
3. The participant will be able to develop a rational diagnostic workup for a patient with a potential functional neurologic disorder.

**Title:** “Managing Functional Neurological Disorders in the Emergency Department”

1. The participant will be able to describe the approach to diagnosis of functional neurologic disorders using positive “rule in” signs.
2. The participant will be able to discuss initial management of functional neurologic disorders in the ED.
3. The participant will be able to discuss the challenges/pitfalls of identifying and managing functional neurologic disorders in the ED.

**Indiana Neurological Society**

**Functional Neurological Disorders: They're Not Fake News**

**Friday, November 3, 2023**

**Wyndham Indianapolis West Hotel**

**PROGRAM EXHIBITORS\***

Abbvie - Migraine	Horizon Therapeutics - TED
Abbvie – Parkinson’s Disease	Jazz Pharmaceuticals
Acadia	LivaNova
Alexion	Lundbeck
Amneal Pharmaceuticals	Mallinckrodt Pharmaceuticals
Axsome Therapeutics	Novartis
Argenx	NS Pharma
Catalyst Pharma -Epilepsy	Sandoz
Catalyst Pharma - LEMS	Sanofi Genzyme - Rare Diseases
EMD Serono	SK Life Sciences
Genentech/Roche	TG Therapeutics
Harmony Biosciences	UCB
Horizon Therapeutics –NMOSD	

*\*The aforementioned companies, providing exhibits, had no influence on the development, planning, or execution of any part of this program. The compensation from these companies, for their exhibits, is not being used to reimburse any of the expenses directly related to this accredited educational program.*

**The Indiana Neurological Society wishes to gratefully acknowledge these organizations for their generous support.**

# **Epidemiology, Etiology, and Pathophysiology of Functional Neurological Disorders**

Mark Hallett, MD, FAAN



Functional Neurological Disorders  
Epidemiology, Etiology, Pathophysiology

**Mark Hallett, M.D.**

Human Motor Control Section, NINDS, Bethesda



National Institute of  
Neurological Disorders  
and Stroke

# Disclosures

- I have no *relevant* disclosures
- *Irrelevant* disclosures
  - I am one of the inventors of an NIH patent for a “Coil for Magnetic Stimulation and methods for using the same (H-coil)” and receive a share of license fee payments from the NIH (coming from Brainsway).
  - Member of the Medical Advisory Boards of Brainsway, QuantalX, and VoxNeuro.
  - Consultant Janssen Pharmaceutical

# Functional Neurological Disorders

*AKA*

- Psychogenic neurological disorders
- Hysteria
- Conversion disorders
- Dissociative disorders

# Functional Neurological Disorders

(my definition)

- A neurological disorder, characterized by **almost any type of neurological symptom**,
- **not voluntarily produced**,
- caused by a **brain network dysfunction** that does not exclude the possibility of normal function,
- **sometimes due in part to a psychological cause**, and
- **not explained by other neurological pathology** that may or may not be present.
- Symptoms may be **inconsistent (variable)** or **incompatible (incongruent)** with other known neurological disorders or human anatomy and physiology.

# Somatic Symptom & Related Disorders

DSM-5-TR

- Somatic Symptom Disorder
- Illness Anxiety Disorder
- **Functional Neurological Symptom Disorder  
(Conversion Disorder)**
- Psychological Factors Affecting Other Medical Conditions
- Factitious Disorder
- Other Specified Somatic Symptom & Related Disorder
- Unspecified Somatic Symptom & Related Disorder



# Somatic Symptom & Related Disorders

DSM-5-TR

- Somatic Symptom Disorder
- Illness Anxiety Disorder
- Functional Neurological Symptom Disorder (Conversion Disorder)
- Psychological Factors Affecting Other Medical Conditions
- Factitious Disorder
- Other Specified Somatic Symptom & Related Disorder
- Unspecified Somatic Symptom & Related Disorder
- (Malingering) – not a condition on this list

# Types of FNDs

- (Psychogenic) Nonepileptic Seizures (PNES)
- Functional Movement (Motor) Disorders
- Functional Sensory Symptoms
- Functional coma
- Functional visual loss, auditory disorders
- Functional eye movement disorders
- Functional speech disorders
- Functional memory disorders
- Functional dizziness (PPPD)
- Functional urologic symptoms
- Functional disorders of swallowing



# Epidemiology

- Incidence: FND 4-12/100,000; FMD 4-5/100,000
- Prevalence: 50/100,000
- Neurology Hospital admissions 9% (Beharry et al. 2021)
- Neurology Clinics (Stone et al. 2010)
  - 5.4% had a primary diagnosis of FND
  - 30% FND was a part of the diagnosis
- Women are 60-75% of patient population
- Data as summarized in Espay et al. 2018 *JAMA Neurology* and O'Mahony et al. 2023 *Neurology*


International online survey of 1048 individuals with functional neurological disorder

Matthew Butler<sup>1</sup> | Oliver Shipston-Sharman<sup>2</sup> | Mathieu Seynaeve<sup>1</sup> | Jianan Bao<sup>1</sup> |  
 Susannah Pick<sup>1</sup> | Abigail Bradley-Westguard<sup>3</sup> | Evellina Ilola<sup>1</sup> | Bridget Mildon<sup>4</sup> |  
 Dawn Golder<sup>5</sup> | James Rucker<sup>1</sup> | Jon Stone<sup>6</sup> | Timothy Nicholson<sup>1</sup>

*Eur J Neurol.* 2021;28:3591-3602.



# Can FMD be clustered into subtypes?



Cite this article: Gilmour GS, Langer LK, Lang AE, MacGillivray L, and Lidstone SC (2023). Neuropsychiatric phenotypes in functional movement disorder. *CNS Spectrums* <https://doi.org/10.1017/S1092852923002353>

Attack treatment, grounding, cognitive behavioural therapy, anxiety treatment

**Possible Therapeutic Strategies**

Motor retraining physiotherapy, graded activity, support agency, address avoidance patterns

# Impact on disability & QOL

Anderson et al. 2007

- 66 patients with PMD compared with 704 patients with PD
- Similar levels of disability on the OARS
- Similar level of physical health QOL
- Worse level of mental health QOL
- Higher levels of distress, anxiety, depression and somatization











# Mortality in patients with psychogenic nonepileptic seizures

Russell Nightscales, BSc(Hons), Lara McCartney, MBBS, Clarissa Auvrez, MD, Gerard Tao, MD, Sarah Barnard, MIPH, Charles B. Malpas, PhD, Piero Perucca, MD, PhD, Anne McIntosh, PhD, Zhibin Chen, MBiostat, PhD, Shobi Sivathamboo, PhD, Sophia Ignatiadis, MSc, Simon Jones, MBBS, Sophia Adams, MBBS, PhD, Mark J. Cook, MD, Patrick Kwan, MD, PhD, Dennis Velakoulis, MBBS, Wendy D'Souza, MBChB, PhD,\* Samuel F. Berkovic, MD,\* and Terence J. O'Brien, MD\*

*Neurology*<sup>®</sup> 2020;95:e643-e652. doi:10.1212/WNL.0000000000009855

- 5508 patients with video-EEG
  - PNES 674, epilepsy 3064, both 175
- Standardized mortality ratio for PNES was 2.5
  - No difference among groups
- 20% of deaths due to suicide in those <50 years of age

## Prevalence of ictal injuries in functional (psychogenic nonepileptic) seizures: A systematic review and meta-analysis

Adriana Boschi Moreira<sup>1</sup>  | André Enoch Knochenhauer<sup>1</sup>  |  
Giullia Victória Froehner<sup>1</sup>  | Marcelo Liborio Schwarzbold<sup>1</sup>  |  
Ali Akbar Asadi-Pooya<sup>2,3</sup>  | Izabel Galhardo Demarchi<sup>1</sup>  | Francesco Brigo<sup>4,5</sup>  |  
Katia Lin<sup>1</sup> 

### Key Points

- Over a lifetime, 25% of individuals were injured due to an FS
- During a VEEG examination, .7% of individuals were injured due to an FS
- Only .1% of the functional seizures that occurred during a VEEG examination caused an injury; they were exclusively oral injuries



## Note Combinations

- Multiple types of movement disorders
- Combination with other neurological disorders, examples:
  - Multiple sclerosis
  - Parkinson disease

# Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders

Christopher D. Stephen, MB ChB, MRCP(UK), MS; Vicki Fung, PhD; Codrin I. Lungu, MD; Alberto J. Espay, MD, MSc

The annual cost is more than \$1.2 billion dollars....comparable to ALS, MS, epilepsy

---

## Economic Cost of Functional Neurologic Disorders

A Systematic Review

Brian O'Mahony, MB BCh, BAO, Glenn Nielsen, BSc, PhD, Sallie Baxendale, PhD, Mark J. Edwards, MBBS, BSc, PhD, FRCP, FEAN, and Mahinda Yogarajah, MD

*Neurology*® 2023;101:e202-e214. doi:10.1212/WNL.0000000000207388

Correspondence

Dr. Yogarajah  
mahinda.yogarajah@nhs.net

The annual cost per person ranged from \$4,964–\$86,722 in 2021 US dollars

---

Current Neurology and Neuroscience Reports  
<https://doi.org/10.1007/s11910-023-01298-8>

Published online: 11 September 2023

REVIEW



## The Financial Burden of Functional Neurological Disorders

Meagan Watson<sup>1</sup> · Jared Woodward<sup>1</sup> · Laura A. Strom<sup>1</sup>

Review of the issues.

## Frequency of Types of FMD

<b>Predominant movement feature</b>	<b>No.</b>	<b>Percent</b>
Tremor	467	37.5
Dystonia	365	29.3
Myoclonus	146	11.7
Gait disorder	114	9.2
Parkinsonism	60	4.8
Tics	29	2.3
Other	64	5.1
<b>Total</b>	<b>1245</b>	<b>100</b>

Table from Jankovic et al. 2021; Data from Lang in Hallett et al 2006

# Understanding disease



# Biopsychosocial Model

- Etiology of FMD is multifactorial
- Basic **bio**logy—genetics, stress responsivity
- **Psycho**logic factors—depression, anxiety
- **Social** factors—physical and emotional trauma; childhood abuse



# Biopsychosocial Model

- The factors can interact
- For example:
  - Early childhood trauma can lead to changes in the developing brain, such as a larger size of the amygdala and epigenetic changes of specific genotypes, that will lead to less resilience to stress in later life and propensity to anxiety and depression, as well as the development of an FND



ORIGINAL RESEARCH

## Effects of *TPH2* gene variation and childhood trauma on the clinical and circuit-level phenotype of functional movement disorders


Primavera A Spagnolo <sup>1</sup>, Gina Norato,<sup>2</sup> Carine W Maurer,<sup>3</sup> David Goldman,<sup>4</sup> Colin Hodgkinson,<sup>4</sup> Silvina Horovitz,<sup>1</sup> Mark Hallett <sup>1</sup>

*J Neurol Neurosurg Psychiatry* 2020;**0**:1–8. doi:10.1136/jnnp-2019-322636

- Sixty-eight patients with a diagnosis of FMD
- Subjects were predominantly female (73%) and Caucasian (89%), with a mean age of 46.7 years  $\pm$  8.3 [range 21–60]
- 53% reported exposure to childhood trauma
- TPH2 is tryptophan hydroxylase-2 (rs4570625)
  - Gene is relevant for serotonin synthesis

## Results


The G-703T polymorphism in *TPH2* was a significant predictor of FMD age of onset





## Results

T carriers exhibited decreased resting state functional connectivity between the R amygdala and the R middle frontal gyrus (uncinate fasciculus)



# Epigenetics

- Spagnolo, Johnson, Hodgkinson, Goldman, Hallett (2023)  
Progress in Neuropsychopharmacology & Biological Psychiatry  
(in press)
- Study of the methylome in FMD patients
- Affected genetic pathways related to childhood abuse and sex
  - Stress
  - Pain

# Psychopathology and Psychogenic Movement Disorders

Movement Disorders 2011:26:1844

Sarah Kranick, MD,<sup>1</sup> Vindhya Ekanayake, BA,<sup>2</sup> Valeria Martinez, MS,<sup>1</sup> Rezvan Ameli, PhD,<sup>3</sup> Mark Hallett, MD,<sup>1</sup>  
and Valerie Voon, MD, PhD<sup>1,4\*</sup>

**TABLE 3.** Psychiatric disorders, depression, and anxiety

	PMD	HVs	FHD	Chi-square or <i>F</i>	<i>P</i> value
SCID (%)					
Major depression (lifetime)	37.1%		33.3%	0.2	.83
Generalized anxiety disorder	20.0%		15.3%	0.4	.61
Phobia	14.3%		12.8%	0.03	1.0
Panic disorder	2.9%		2.6%	0.03	1.0
Beck Depression Inventory	10.7 (8.4, 57)	4.0 (4.7, 38)	6.4 (5.6, 28)	11.6	< .0001
Beck Anxiety Inventory	14.6 (9.8, 58)	2.6 (3.9, 38)	6.1 (6.8, 28)	31.7	< .0001

# Stressful life events and maltreatment in conversion (functional neurological) disorder: systematic review and meta-analysis of case-control studies

*Lancet Psychiatry* 2018


Published Online

March 8, 2018

[http://dx.doi.org/10.1016/](http://dx.doi.org/10.1016/S2215-0366(18)30051-8)

S2215-0366(18)30051-8

Lea Ludwig, Joëlle A Pasman, Timothy Nicholson, Selma Aybek, Anthony S David, Sharon Tuck, Richard A Kanaan, Karin Roelofs, Alan Carson, Jon Stone





## Gender disparity and abuse in functional movement disorders: a multi-center case-control study

Isaiah Kletenik<sup>1,2,3</sup> · Samantha K. Holden<sup>2,3,4</sup> · Stefan H. Sillau<sup>2</sup> · Nicola O'Connell<sup>5</sup> · Lindsey MacGillivray<sup>6</sup> · Joel Mack<sup>7,8</sup> · Beatrix Haddock<sup>9</sup> · M. Ashworth Dirac<sup>9,10</sup> · Anthony S. David<sup>11</sup> · Timothy R. Nicholson<sup>12</sup> · Sanaz N. Attaripour Isfahani<sup>13</sup> · Carine W. Maurer<sup>14</sup> · Sarah C. Lidstone<sup>15</sup> · Mark Hallett<sup>16</sup> · Kathrin LaFaver<sup>17,18</sup> · Brian D. Berman<sup>2,4,19</sup> · Jon Stone<sup>20</sup>

696 subjects (512 women); 141 controls (98 women) + population controls

	Subjects		Controls	
	Women	Men	Women	Men
Sexual abuse	35.3%	11.5%	10.6%	5.6%


For Women (only)

Likelihood of FMD with sexual abuse: 4.57 (95% confidence limits 2.31 – 9.07)


Population attributable fraction from sexual abuse: 0.12 (95% confidence limits 0.05 – 0.19)

# VBM in FMD


## Gray Matter Increases Associated with FMD



L amygdala



L putamen



L caudate; bilateral thalami

**n = 48 FMD**  
**n = 55 HV**


$p < 0.05$  (whole brain corrected)

Maurer et al. *Neurology* 2018

Sensitive periods of amygdala development: The role of maltreatment in preadolescence

NeuroImage 97 (2014) 236–244


Pia Pechtel<sup>a,e,\*</sup>, Karlen Lyons-Ruth<sup>b,e</sup>, Carl M. Anderson<sup>c,d,e</sup>, Martin H. Teicher<sup>c,e</sup>



# Identification of biopsychological trait markers in functional neurological disorders

BRAIN 2023; 146; 2627–2641

© Samantha Weber,<sup>1,2,3</sup> © Janine Bühler,<sup>1,2,4</sup> Giorgio Vanini,<sup>1</sup> © Serafeim Loukas,<sup>1,5,6</sup>  
© Rupert Bruckmaier<sup>7</sup> and © Selma Aybek<sup>1,2</sup>





# Reactivation of Early-Life Stress-Sensitive Neuronal Ensembles Contributes to Lifelong Stress Hypersensitivity

Julie-Anne Balouek, Christabel A. McLain, Adelaide R. Minerva, Rebekah L. Rashford, Shannon N. Bennett, Forrest D. Rogers, and Catherine Jensen Peña

The Journal of Neuroscience, August 23, 2023 • 43(34):5996–6009

- ❖ In mice, early life stress activates neuronal ensembles in nucleus accumbens and medial prefrontal cortex (mPFC)
  - ❖ Inhibition of these neurons, when mice are adult, reduces social avoidance behavior following chronic social defeat
- 

## Sex-Specific Timelines for Adaptations of Prefrontal Parvalbumin Neurons in Response to Stress and Changes in Anxiety- and Depressive-Like Behaviors

Emma Woodward,<sup>1,\*</sup>  Claudia Rangel-Barajas,<sup>3,\*</sup> Amanda Ringland,<sup>2</sup>  Marian L. Logrip,<sup>3,4</sup> and  Laurence Coutellier<sup>1,2</sup>


March 2023, 10(3) ENEURO.0300-22.2023 1–19

- ❖ In mice, chronic mild stress increases activity of parvalbumin interneurons in mPFC
- ❖ This is more in females than males

# DTI in FMD

## White Matter Changes Associated with FMD


Right  
uncinate  
fasciculus



# Aberrant Maturation of the Uncinate Fasciculus Follows Exposure to Unpredictable Patterns of Maternal Signals

The Journal of Neuroscience, February 10, 2021 • 41(6):1242–1250


Steven J. Granger,<sup>1,2</sup> Laura M. Glynn,<sup>3</sup> Curt A. Sandman,<sup>4</sup> Steven L. Small,<sup>5</sup> Andre Obenaus,<sup>6</sup> David B. Keator,<sup>4</sup> Tallie Z. Baram,<sup>1,6,7</sup> Hal Stern,<sup>8</sup> Michael A. Yassa,<sup>1,2,4</sup> and Elysia Poggi Davis<sup>4,9</sup>



# Impaired resting vagal tone in patients with functional movement disorders

Carine W. Maurer<sup>a,\*</sup>, Victoria D. Liu<sup>a</sup>, Kathrin LaFaver<sup>a,b</sup>, Rezvan Ameli<sup>c</sup>, Tianxia Wu<sup>d</sup>, Ryan Toledo<sup>a</sup>, Steven A. Epstein<sup>e</sup>, Mark Hallett<sup>a</sup>

*Parkinsonism and Related Disorders* 30 (2016) 18–22




RMSSD = root mean square of successive differences between adjacent NN intervals


Impaired resting state vagal tone may reflect increased stress vulnerability

# Biopsychosocial Model

- Etiology of FMD is multifactorial
- Basic **bio**logy—genetics, stress responsivity
- **Psycho**logic factors—depression, anxiety
- **Social** factors—physical and emotional trauma; childhood abuse
- One apparent result is overactivity of the limbic system


# Understanding disease







A Bayesian network

Pezzulo et al. 2021 Phil Trans R Soc B 377: 20200531




Neural correlate of belief may be in the insula and associated parts of frontal cortex








## Affect processing and the right amygdala in FMD



Fearful face




Happy face



Voon, V. et al. *Brain* 2010 133:1526-1536; doi:10.1093/brain/awq054

Aybek S, Nicholson TR, O'Daly O, Zelaya F, Kanaan RA, et al. (2015)  
Emotion-Motion Interactions in Conversion Disorder: An fMRI Study.  
PLOS ONE 10(4): e0123273. <https://doi.org/10.1371/journal.pone.0123273>





**Fig 1. ROI analysis: Group effect in the Emotion Model.**

# Aberrant Supplementary Motor Complex and Limbic Activity During Motor Preparation in Motor Conversion Disorder

Valerie Voon, MD PhD,<sup>1\*</sup> Christina Brezing, MD,<sup>2</sup> Cecile Gallea, PhD,<sup>2</sup> and Mark Hallett, MD<sup>2</sup>


*Movement Disorders*, Vol. 26, No. 13, 2011





# Startle responses in functional jerky movement disorders are increased but have a normal pattern

Parkinsonism and Related Disorders 40 (2017) 27–32


Y.E.M. Dreissen, MD<sup>a</sup>, T. Boeree<sup>a</sup>, J.H.T.M. Koelman, MD, PhD<sup>a</sup>, M.A.J. Tijssen, Prof<sup>b,\*</sup>



Exaggerated startle responses may arise from overactive limbic system (amygdala)



# Regions responding proportionally to the loss of self-agency





Nahab F B et al. *Cereb. Cortex* 2011;21:48-55



# Less modulation of self-agency in patients with FMD

**Citation:** Nahab FB, Kundu P, Maurer C, Shen Q, Hallett M (2017) Impaired sense of agency in functional movement disorders: An fMRI study. PLoS ONE 12(4): e0172502. <https://doi.org/10.1371/journal.pone.0172502>





Arrow: R TPJ



Area of **hypoactivity**  
with functional tremor  
compared with  
voluntary mimic

TPJ = temporoparietal junction


And decreased connectivity of the R TPJ to the  
sensorimotor cortex & ventral anterior cingulate



**Voon et al. *Neurology* 2010;74:223-228**



## Resting state fMRI

**Figure 1** Decreased functional connectivity (FC) between the right temporo-parietal junction (rTPJ) and bilateral sensorimotor regions in patients with functional movement disorders (FMD)





# How can active inference cause functional movements?


Compare tics...

[doi:10.1093/brain/awl050](https://doi.org/10.1093/brain/awl050)



Brain (2006), 129, 2029–2037


## Neural correlates of tic generation in Tourette syndrome: an event-related functional MRI study

S. Bohlhalter, A. Goldfine,\* S. Matteson,\* G. Garraux, T. Hanakawa, K. Kansaku, R. Wurzman and M. Hallett





**Fig. 2** Statistical parametric maps superimposed on axial (A), coronal (B) and sagittal (C and D) views are shown. The upper row shows significant activations ( $P < 0.05$ , corrected for multiple comparisons) of paralimbic areas (ACC and insular region bilaterally) before tic onset; these activations were much less prominent at tic onset (lower row).





**TREATMENT** ←








# Clinical and neural responses to cognitive behavioral therapy for functional tremor

Alberto J. Espay, MD, MSc, Scott Ries, LISW, Thomas Maloney, MS, Jennifer Vannest, PhD, Erin Neefus, BS, CCRP, Alok K. Dwivedi, PhD, Jane B. Allendorfer, PhD, Lawson R. Wulsin, MD, W. Curt LaFrance, Jr, MD, MPH, Anthony E. Lang, MD, FRCPC, and Jerzy P. Szaflarski, MD, PhD

*Neurology*® 2019;93:e1787-e1798. doi:10.1212/WNL.0000000000008442





# **Amygdala and Insula Connectivity Changes Following Psychotherapy for Posttraumatic Stress Disorder: A Randomized Clinical Trial**

Gregory A. Fonzo, Madeleine S. Goodkind, Desmond J. Oathes, Yevgeniya V. Zaiko, Meredith Harvey, Kathy K. Peng, M. Elizabeth Weiss, Allison L. Thompson, Sanno E. Zack, Steven E. Lindley, Bruce A. Arnow, Booil Jo, Barbara O. Rothbaum, and Amit Etkin

Biological Psychiatry May 1, 2021; 89:857–867

# Simple summary

- FNDs are common, disabling, and expensive.
- FNDs are multifactorial in etiology, best understood by the biopsychosocial model
- FNDs are involuntary
- Pathophysiology, triggered by limbic overactivity, may arise from abnormal belief driving a feedforward-feedback (Bayesian) network



Functional Neurological Disorder Society

[www.FNDSociety.org](http://www.FNDSociety.org)


[info@FNDSociety.org](mailto:info@FNDSociety.org)

(414) 918-9814

8-11 June 2024

**VERONA**

*Italy*



**FUNCTIONAL  
NEUROLOGICAL  
DISORDER  
SOCIETY**



**5TH INTERNATIONAL CONFERENCE ON FUNCTIONAL NEUROLOGICAL DISORDER**

[www.FNDSociety.org](http://www.FNDSociety.org)

# **Functional Movement Disorders**

Sarah Lidstone, MD, PhD



# Functional Movement Disorders: clinical presentations and treatment approaches

November 3, 2023

Sarah C. Lidstone M.D., Ph.D.

Director, Integrated Movement Disorders Program, Toronto Rehabilitation Institute

Movement Disorders Neurologist, University Health Network

Assistant Professor, University of Toronto

Affiliate Scientist, KITE, Toronto Rehabilitation Institute

# Disclosures

- Royalties from UptoDate article “Functional Movement Disorder”

# Outline

- Part 1: Review of FMD positive signs and phenotypes
- Part 2: 5 lessons about FMD relevant for treatment
- Part 3: Practical tips and therapy approaches for the neurologist

Please no recording.

Patients shown have provided consent for videos to be used for educational purposes, only.



# Part 1: Review of FMD positive signs and phenotypes

---

# FMD phenotype frequency


**Table 1** Descriptive summary statistics and one-stage individual patient data meta-analysis mixed-effects linear regression model for age of symptom onset, with 'tremor' and 'female' as the reference categories


	n (%)	Age of onset Mean (SD)	Gender Women (%)	Coefficient (95% CI)	Standardised effect size (95% CI)	P value
<b>Gender</b>						
Women	3558 (72.5)	39.1 (15.9)	–	–	–	–
Men	1347 (27.5)	41.0 (16.5)	–	1.66 (0.71 to 2.62)	0.10 (0.04 to 0.16)	0.001*
<b>Phenotype</b>						
Mixed	1127 (23.0)	42.1 (16.3)	848 (75.2)	0.32 (–1.05 to 1.69)	0.02 (–0.07 to 0.10)	0.649
Tremor	1056 (21.6)	40.7 (16.6)	752 (71.2)	–	–	–
Weakness	887 (18.1)	36.4 (13.4)	647 (72.9)	–3.74 (–5.35 to 2.14)	–0.23 (–0.33 to 0.13)	<0.001*
Dystonia	578 (11.8)	34.5 (14.8)	453 (78.4)	–4.31 (–5.98 to 2.65)	–0.27 (–0.37 to 0.16)	<0.001*
Gait	405 (8.3)	43.2 (18.4)	284 (70.1)	3.21 (1.39 to 5.03)	0.20 (0.09 to 0.31)	0.001*
Jerks/myoclonus	223 (4.5)	39.8 (18.7)	142 (63.7)	1.03 (–1.19 to 3.25)	0.06 (–0.07 to 0.20)	0.363
Parkinsonism†	83 (1.7)	44.6 (12.9)	43 (51.8)	–	–	–
Facial symptoms†	67 (1.4)	37.3 (12.6)	56 (83.6)	–	–	–
Other/unknown	479 (9.8)	40.3 (15.8)	333 (69.5)	–1.11 (–3.19 to 0.98)	–0.07 (–0.20 to 0.06)	0.298
Total sample	4905 (100.0)	39.7 (16.1)				

Coefficients are to be interpreted in terms of age at onset in years; and standardised coefficients are interpreted in SD. Positive coefficient means that the variable was associated with a later age of onset and negative coefficient with an earlier age of onset.


\*Statistically significant at the  $p < 0.05$  level.

†Not inputted into linear regression model.










Co-contraction  
Entrainment  
"Whack-a-mole"  
Coherence  
Contralateral ballistic movement




Resistance to passive ROM



Hip abductor sign  
Collapsing weakness



Astasia-abasia  
Tight-rope  
Uneconomical gait  
Knee buckling  
Walking on ice  
Leg dragging  
Excessive slowness



Entrainment  
Axial/facial distribution



Self-injury  
Wide repertoire, lack of stereotype  
Adult onset  
Lack of urge\*  
Not suppressible



Slowness without decrement  
Paratonia  
Preserved speed  
Automatic tasks

# Variability

---

Changing patterns of the abnormal movements over time

- Distribution
- Amplitude
- Frequency
- Phenomenology

# Inconsistency

Movement impaired at some times and preserved in others; inconsistent performance on examination and times when the patient is not being actively examined

# Distractibility



Abnormal movements  
resolve during cognitive  
or motor tasks\*

\*the patient must be truly  
distracted

# Enhancement with attention



Abnormal movement  
worsens/emerges when  
attention is drawn to it



# Incongruency

Clinical picture is incompatible with other neurological diseases

# Entrainment



Tremor/jerks take the same frequency of an externally cued rhythmic movement

# Co-contraction

Simultaneous contraction of agonist and antagonist muscles resulting in little movement +/- tremor

# “Whack-a-mole” sign


Emergence or worsening of an involuntary movement in a separate body part when initially affected body part is restrained by examiner




# Hoover sign

- Most useful in asymmetrical leg weakness
- May be present in patients not complaining of weakness
- Hip abduction hoover sign useful if bed bound or bilateral leg weakness
- If present is extremely useful for explaining the diagnosis to the patient

A Hoover sign in the weak leg



# Functional Dystonia



# Exploratory Neuropsychiatric Phenotypes: Movement Disorder

**Table 5.** Logistic Regression Models Examining Relationships between Functional Movement Disorder Phenotype and Episodic vs. Constant Symptoms

Independent variables	Episodic phenotype			Constant phenotype		
	OR	95% CI	P	OR	95% CI	P
Gait disorder	0.35	0.15-0.84	.019	7.32	3.07-17.48	<.0001
Tremor	5.41	2.14-13.72	.0004	0.83	0.36-1.95	.673
Weakness	0.70	0.24-2.07	.522	4.88	1.76-13.53	.002
Appendicular jerks	11.32	4.12-31.14	<.0001	0.32	0.12-0.78	.013
Fixed dystonia	1.01	0.17-6.16	.989	12.36	1.89-80.94	.009
Axial jerks	20.86	2.33-187.09	.007	0.45	0.08-2.56	.369
Facial movements	2.88	0.78-10.57	.112	1.33	0.40-4.43	.647
Parkinsonism	2.02	0.22-18.78	.538	0.40	0.05-3.33	.398

Abbreviations: CI, confidence interval; OR, odds ratio.

# FMD-Relevant Factors

- Recurrent, observable **behavioural patterns** noted in patients with FMD
- Factors are drawn from psychiatry literature and clinical experience
  - Some have been previously associated with FMD, others are recognized phenomena in psychiatry
- May not be routinely assessed by neurologists or psychiatrists
- **Not inherently pathological or etiological for FMD** → May contribute to the expression of FMD acting as predisposing or precipitating factors





<p><b>Activity Avoidance:</b> Limiting activities due to fear of symptom exacerbation either during or after activity</p>	<p><b>Propensity to Dissociate:</b> Tendency towards disconnections from one’s thoughts, feelings, actions and sense of self. May be directly observed or described from patient experience</p>
<p><b>Emotional Avoidance:</b> Tendency to avoid experiencing or expressing uncomfortable emotions, either directly expressed by patient, evident as a pattern or clearly visible during clinic</p>	<p><b>Somatic Preoccupation/Health Anxiety:</b> Preoccupation and excessive worry/attention to bodily symptoms, time and energy spent on symptoms, worry</p>
<p><b>“Go-Go-Go” Coping Style:</b> Self-report of constantly keeping busy, highly productive and discomfort with free time when not attending to a goal</p>	<p><b>Border Traits:</b> Not diagnosed with a personality disorder, but with overlapping traits including emotional dysregulation, help-seeking-help-</p>
<p><b>Hyperarousal:</b> Elevated and activation, hyper-talkativeness, diffuse hyperreflexia without upper motor neuron signs, diaphoresis, visible muscle tension, fidgeting, fist clenching</p>	<p><b>Tendency toward People Pleasing:</b> Self-reported strong urge to attend to others’ needs and wants at the expense of their own, high responsibility taking</p>
<p><b>Low Self-Agency:</b> Feeling a lack of control over self or environment, tendency to allow others to provide care needs, tendency to attribute success/failure to others, evident by historical patterns</p>	<p><b>Tendency Toward Perfectionism:</b> Self-reported striving for perfection, critical self-evaluation, pressure to achieve unrealistic goals</p>


**This list is not exhaustive!**

**These are not pathological!**

# Neuropsychiatric phenotypes in functional movement disorder

Gabriela S. Gilmour<sup>1,2</sup> , Laura K. Langer<sup>3</sup>, Anthony E. Lang<sup>1,2</sup>,  
Lindsey MacGillivray<sup>4,5,6</sup> and Sarah C. Lidstone<sup>2,3,4</sup> 


N=160 consecutive FMD patients  
Movement disorders evaluation at 2 time points  
Psychiatric FND evaluation



Depression ↔ Gait Disorder

Low Self-Agency ↔ Weakness

Hyperarousal ↔ Appendicular Jerks/  
Myoclonus



Attack treatment, grounding, cognitive behavioural therapy, anxiety treatment

**Possible Therapeutic Strategies**

Motor retraining physiotherapy, graded activity, support agency, address avoidance patterns

*Gilmour et al. 2023*

# Episodic FMD

**Movement: hyperkinetic motor symptoms**

**FMD Factors: anxiety, hyperarousal, history of trauma**

39-year-old man, history IBS

- Onset: 6 months prior
- Primary symptoms: **episodic axial jerks** originating from area of abnormal sensation on back, stuttering speech
- FMD-Relevant Factors: **anxiety, hyperarousal**, emotional avoidance
- Experienced chronic adversity with ex-wife

# Constant FMD

**Movement: gait disorder, weakness, fixed dystonia**  
**FMD Factors: activity avoidance, low self-agency**

20-year-old woman

- Onset: 2 years ago, after suspected viral encephalitis
- Primary symptoms: **constant** generalized weakness, fatigue, cognitive fog
- FMD-Relevant Factors: **activity avoidance, low self-agency, propensity to dissociate, perfectionism**

Part 2: 5 lessons  
about FMD relevant  
for treatment


---

1. FMD is a syndrome beyond the movement disorder







# FMD is a syndrome



*Gilmour and Lidstone in press*






Original research

## Functional movement disorder gender, age and phenotype study: a systematic review and individual patient meta-analysis of 4905 cases

Sarah C. Lidstone <sup>1,2</sup> Michael Costa-Parke,<sup>1</sup> Emily J. Robinson,<sup>3,4</sup>  
Tommaso Ercoli <sup>5</sup> Jon Stone <sup>6</sup> FMD GAP Study Group



# Motor phenotype changes in 40% of patients

**Supplemental Table 1.** Functional movement disorder phenotypic change between assessments

Phenotype	Change			No change
	Any change	Gained	Lost	
All phenotypes ( <i>n</i> = 139)	58 (42%)	33 (24%)	45 (32%)	81 (58%)
<b>Movement phenotype</b>				
Appendicular jerks	19 (33%)	9 (16%)	10 (17%)	39 (67%)
Gait	18 (26%)	6 (9%)	12 (17%)	52 (74%)
Weakness	13 (35%)	2 (5%)	11 (30%)	24 (65%)
Tremor	10 (17%)	4 (7%)	6 (10%)	50 (83%)
Facial	7 (29%)	5 (21%)	2 (8%)	17 (71%)
Fixed dystonia	4 (36%)	1 (9%)	3 (27%)	7 (64%)
Parkinsonism	3 (43%)	0	3 (43%)	4 (57%)
Tics	2 (40%)	1 (20%)	1 (20%)	3 (60%)
Axial jerks	1 (8%)	1 (8%)	0	11 (92%)
<b>Episodic/constant symptoms</b>				
Episodic	21 (21%)	11 (11%)	10 (10%)	78 (79%)
Constant	17 (28%)	4 (7%)	13 (21%)	44 (72%)

Not associated with duration between appointments (*p* = 0.58)

FND  
Phenotypes  
("the leaves")

Vestibular sx   Tremor   Weakness/paralysis   Attacks or seizures  
Visual, olfactory sx   Sensory loss   Gait disorders  
Dystonia   Bladder/bowel   Myoclonus   Speech/swallowing   Coma

Pain, fatigue, cognitive disorders

Altered nervous  
system reactivity

Hyperarousal/  
Somatic anxiety   Autonomic dysregulation   Dissociation

FND engine/  
formulation  
("the roots")

Personality traits   Coping style   Somatization   Low agency   Triggering event  
Unconscious needs   Attachment style   Trauma/neglect   Perfectionism

Psychosocial environment  
("the soil")

## 2. Functional and structural symptoms coexist

# Throw out the dualism

- Neurological symptoms/disease is the largest risk factor for FND
- Functional/dissociative seizures and epilepsy comorbidity is 30%
- Functional tremor or parkinsonism can occur in prodromal Parkinson's disease
- Chronic illness of any kind is a risk factor for functional symptoms


## The big idea: should we drop the distinction between mental and physical health?

The current false dichotomy holds back research and stigmatises patients




Illustration: Elia Barbieri

# “Your symptoms are very real...to you”





## Impact of stigma in the clinical encounter in FND



# 3. FMD is treatable\*

\*but not for everyone at that time




# FND treatment is opt in


- Therapy cannot be done TO the patient
- Successful outcomes depend on:
  - Active engagement by the patient
  - Realistic and specific goals for improvement
  - Diagnostic agreement
  - Minimizing barriers to rehabilitation (e.g. pain, fatigue, cognitive)
  - Alignment of patient goals with skill set of the team



# FMD treatment options

- Diagnosis and education
- Motor retraining physiotherapy
- Mind-body therapies
- Psychotherapy
  - Adapted Cognitive Behavioural Therapy
  - Psychodynamic psychotherapy (intensive, short- or long-term)
- Multidisciplinary rehabilitation
- Treat comorbid conditions (anxiety, chronic pain, trauma therapy, etc.)





**Fig. 20.2** Example of patient triage into specialist physiotherapy for patients with functional movement disorder (Diagram adopted with permission from Nielsen et al. 2017)

# Red flags for rehab: not the time




- Unable to notice inconsistency or positive signs when shown
- “What will you do to fix me?” = low agency
- “I will do anything to get better”+ many failed Tx’s = help seek, help reject pattern (cluster B trait)
- Polysymptomatic functional syndrome = somatization (i.e. not FMD)
- Chronic and coping -> can be destabilized by a new illness model
- Negative syndrome (weakness/fatigue/wheelchair) = avoidance
- Facial symptoms = unexpressed anger
- Active litigation

# Before treatment




4. Recovery potential is determined by perpetuating factors





# Biopsychosocial model for FND



*Gilmour and Lidstone  
In press*


# Chronic FMD

- 40% of patients with FMD remain with similar or worse symptoms in the long-term
- Numerous reasons patients become “stuck”
  - Implicit needs are being met through illness
  - Maladaptive personality style/coping mechanisms
  - Low/no agency, external locus of control, victimized stance
  - High resistance e.g. persistent unexpressed anger, profound self-stigma
- With earlier diagnosis, better diagnostic explanation and rapid access to appropriate evidence-based treatments, most patients can achieve long-lasting improvement

# Diagnostic disagreement

- Your job is not to convince the patient they have FMD
- Not everyone will agree with you – that's ok!
- An accurate diagnosis, empathy, and validation can counteract previous invalidating health care experiences
- Persistent/entrenched diagnostic resistance usually indicates deeper perpetuating factors

5. Recovery is self-management,  
not the absence of symptoms



# What recovery looks like

# Part 3: Practical tips and therapy approaches for neurologists


---

# Bedside treatment tips

- Noticing when movement is better during automatic movements
  - Incorporate these into the assessment, e.g. taking on/off shoes, putting phone away in purse, moving pillow on the exam bed
- Self-distraction
  - Teach the patient how distraction improves symptoms and attention makes them worse
- Incorporate body relaxation techniques into the neurological exam and point out how the symptoms change
  - Especially useful for hyperkinetic patients



# Hardware-software and distractibility



# Automatic Motor Programs



# Rehab approach: learned automatic movements




# Nervous system overflow



# Nervous system reset



## How Trauma Can Affect Your Window Of Tolerance



# Rehab approach: nervous system “reset”

# Take home points

- FMD is a syndrome with an underlying engine
- Risk and triggering factors are responsible for symptom onset, perpetuating factors are responsible for symptom maintenance
- A good diagnosis and education is the first step in treating FMD and is the role of the neurologist
- FMD is treatable, and treatment needs to be carefully triaged for suitable patients
  - Patient engagement is paramount
- Recovery from FMD is self-management
- Some patients will remain chronic which needs to be considered for resource allocation





**8-11 June 2024**  
**Verona, Italy**

**FUNCTIONAL NEUROLOGICAL DISORDER SOCIETY**  
fndsociety.org

**5th International Conference on Functional Neurological Disorder**





## ***Integrated Movement Disorders Program***

Dr. Lindsey MacGillivray MD, PhD  
Haseel Bhatt MSc, MScPT  
Keschey Marcelle RN, MA, MSc  
Dr. Darcy O'Brien  
Sarine Willis-O'Connor  
Julie Racioppa  
Swati Kumar

- Anonymous donation for Neuromodulation and Multidisciplinary Care

Our patients for their consent to share their videos with you.



## ***Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic***

Dr. Tony Lang  
Dr. Gabriela Gilmour



## ***Toronto Rehabilitation Institute***

Dr. Mark Bayley  
Laura Langer



## ***FNDS***

Dr. David Perez  
Dr. Gaston Baslet  
Julie Maggio  
Dr. Dara Albert  
Robert Kopchinski





# **Persistent Postural-Perceptual Dizziness and Other Functional Vestibular Disorders**

Jeffrey P Staab, MD, MS

Indiana Neurological Society  
2023 Fall Conference

## Persistent Postural-Perceptual Dizziness (PPPD) and other functional causes of dizziness

Jeffrey P. Staab, MD, MS  
Professor and Chair, Department of Psychiatry and Psychology

Consultant, Departments of Psychiatry and Psychology and  
Otorhinolaryngology – Head and Neck Surgery

Mayo Clinic, Rochester, MN USA



03 November 2023

## Disclosures

- Commercial interests
  - None
- Recommendations for off-label use of medications
  - SSRIs/SNRIs for persistent postural perceptual dizziness (PPPD)
  - SSRIs/SNRIs and benzodiazepines for mal de debarquement syndrome (MdDS)
- Discussion of off-label use of neuromodulation
  - Vagal nerve stimulation and transcranial magnetic stimulation for PPPD
  - Transcranial magnetic stimulation for MdDS
- Grant funding
  - U.S. National Institute on Deafness and Other Communication Disorders
  - U.S. Department of Defense via the Congressionally Directed Medical Research Program
  - Mayo Clinic

# Overview

1. Persistent postural perceptual dizziness (PPPD)
  1. History
  2. Diagnostic criteria
  3. Clinical epidemiology
  4. Case examples
  5. Pathophysiologic model
  6. Treatment
2. Mal de debarquement syndrome (MdDS)
  1. Diagnostic criteria
  2. Pathophysiologic model
  3. Treatment
3. Chronic dizziness in somatic symptom disorder
  1. Diagnostic criteria
  2. Treatment

Our focus will be on functional and somatic symptom disorders that manifest vestibular and balance symptoms.

## History – precursor of PPPD

Die Agoraphobie (fear of marketplace)  
“Patients find it impossible to cross open squares and walk along certain streets. Fear restricts their **mobility**, [but] they insist that they are not aware of any reasons for their **anxiety**. It seems to arise as an alien force as soon as a square is crossed or approached. With the anxiety, as part of **one process**, occurs the **thought** of not being able to cross and a **perception** of an enormous expanse of space.”



*Carl Westphal, 1871*

## PPPD – new-ish, but really not new at all

- 1870 – Platzschwindel (Benedikt)
- 1871 – Die Agoraphobie (Westphal)
- 1872 – Platzangst (Cordes)



Psychogenic dizziness


- 1975-1985 – Supermarket syndrome, space phobia, etc.
- 1986 – Phobic postural vertigo (PPV)
- 1993 – Space-motion discomfort (SMD)
- 1995 – Visual vertigo (VID)
- 2004 – Chronic subjective dizziness (CSD)
- 2017 – Persistent postural-perceptual dizziness (PPPD)



## PPPD: International Classification of Vestibular Disorders (ICVD)

- A. Dizziness, unsteadiness, or non-spinning vertigo present on most days for 3 months or more.
  - Symptoms must be present for prolonged (hours-long) periods but need not be continuous throughout the entire day.
- B. Persistent symptoms are present without specific provocation, but are exacerbated by 3 factors:
  - Upright posture, active or passive motion, and exposure to moving visual stimuli or complex visual patterns.
- C. The disorder is triggered by events that cause vertigo, unsteadiness, dizziness, or problems with balance:
  - Acute, episodic, or chronic vestibular syndromes, other neurologic or medical illnesses, and psychological distress.
- D. Symptoms cause significant distress or functional impairment.
- E.** Symptoms are not better accounted for by another disease or disorder.

***PPPD is not a diagnosis of exclusion.***



# PPPD: International Classification of Diseases, 11<sup>th</sup> edition (ICD-11)

## ICD-11 for Mortality and Morbidity Statistics (Version : 02/2022) EN

Search  [\[ Advanced Search \]](#) [Browse](#) [Coding Tool](#) [Special Views](#) [Info](#)

- ▼ 10 Diseases of the ear or mastoid process
  - ▶ Diseases of external ear
  - ▶ Diseases of middle ear or mastoid
  - ▼ Diseases of inner ear
    - ▶ **AB30** Acute vestibular syndrome
    - ▶ **AB31** Episodic vestibular syndrome
    - ▼ **AB32** Chronic vestibular syndrome
      - AB32.0** Persistent Postural-Perceptual Dizziness
      - AB32.1** Chronic unilateral idiopathic vestibulopathy
      - AB32.2** Persistent unilateral vestibulopathy after vestibular neuronitis

Foundation URI : <http://id.who.int/icd/entity/2005792829>

### AB32.0 Persistent Postural-Perceptual Dizziness

**Parent**

[AB32 Chronic vestibular syndrome](#)

Show all ancestors

**Description**

Persistent non-vertiginous dizziness, unsteadiness, or both lasting three months or more. Symptoms are present most days, often increasing throughout the day, but may wax and wane. Momentary flares may occur spontaneously or with sudden movement. Affected individuals feel worst when upright, exposed to moving or complex visual stimuli, and during active or passive head motion. These situations may not be equally provocative. Typically, the disorder follows occurrences of acute or episodic vestibular or balance-related problems. Symptoms may begin intermittently, and then consolidate. Gradual onset is uncommon.

## Clinical epidemiology of PPPD

Location	Point Prevalence of PPPD (Patients with dizziness)	Demographics
Primary care	14%	Sex – 66% F Age – 55 yrs
Neurology clinic	20%	
Specialty dizziness center	10% sole Dx 45% co-existing Dx	
Pediatric balance center	7%	Sex – 83% F Age – 15 yrs

*PPPD is the most common cause of chronic vestibular symptoms in all of these clinical settings.*

Precipitants ( <u>also</u> differential diagnosis)	Philadelphia	Rochester, MN	Munich	Boston (children)
	<u>CSD</u>	<u>CSD</u>	<u>PPPD</u>	<u>PPPD</u>
	N=345	N=103	N=356	N=53
<u>Acute and episodic vestibular syndromes</u>	25%	21%	24%	70%
<u>Anxiety disorders</u>	25%	22%	20%	4%
<u>Neurologic Illnesses</u>				
- migraine	16%	25%	11%	56%
- traumatic brain injury	15%	10%	3%	15%
- autonomic dysregulation	7%	6%	1%	4%
<u>Other Medical Conditions</u>				
- dysrhythmias, metabolic disorders	7%	3%	6%	Structural ear disease 8%

## Case example #1

- 44 yo M awoke with spinning vertigo and gait unsteadiness
  - Not positional or postural
  - No hearing changes, headache, focal neurologic symptoms
  - Vertiginous symptoms gradually improved over 2-4 weeks
  - Now 4 years of swaying/rocking unsteadiness (↑↓)
    - Increased with his own movement, better recumbent
    - Increased in stores, busy social gatherings, traffic
    - Increased using mobile phone, computer

Acute  
vestibular  
syndrome

Chronic  
vestibular  
syndrome

1. Vestibular testing – 54% right peripheral deficit, otherwise normal
  - Acute unilateral vestibulopathy (compensated), then PPPD
2. History of continued brief motion-induced vertigo  
Vestibular testing – 54% right peripheral deficit, positive head impulse test, positive head shake test
  - Acute unilateral vestibulopathy (uncompensated) and PPPD

## Case example #2





- 48 yo F described a 5-year history of recurrent attacks of spinning vertigo lasting hours
  - Attacks occur spontaneously 1-2/month, unsure about triggers (maybe poor sleep)
  - Mild aural fullness and occasional tinnitus, either ear, sometimes bilateral
  - 75% of attacks are followed by a severe headache + photophobia and nausea
  - For the first 2 years, she felt completely normal between attacks
  - Then, dizziness began to linger between attacks, gradually became constant (↑↓)
    - Increased with her own movement
    - Increased in her busy open office, on train, in stores
    - Increased using mobile phone and tablet

Episodic  
vestibular  
syndrome

Chronic  
vestibular  
syndrome

1. Audiogram and vestibular testing – normal (not strictly needed)
2. MRI including IACs, and CT of temporal bone – normal (not strictly needed)
  - **Vestibular migraine and PPPD**

# Illness Profiles: Vertigo, Unsteadiness, Dizziness (N=410)



Sensitivity  
>85%

Specificity  
>85%

## Diagnostic aids

- Self-report questionnaires
  - Early screening (within 90 days of symptom onset) – Retrospective study (N=155)
    - **Niigata PPPD Questionnaire (NPQ)** – total score  $\geq 27$ 
      - Sensitivity = 0.88; Specificity = 0.52
  - Late screening (patients with chronic symptoms) – Two retrospective studies (N=85; N=292)
    - **Dizziness Handicap Inventory (DHI)** – total score  $> 60$ 
      - Specificity = 0.88: functional disorders (mostly PPPD) or psychiatric illness
- Vestibular laboratory tests and neuroimaging
  - The diagnosis of PPPD is based on clinical history.
    - Core symptoms (criterion A) and responses to exacerbating factors (criterion B).
  - Lab testing and imaging may be needed to work through the differential diagnosis.
    - To evaluate the clinical state of precipitants (criterion C).
    - To consider co-existing conditions (criterion E).



## Red Flags that it's Not PPPD

- Indistinct onset, slowly progressive symptoms
  - Neurodegenerative disorder
    - Peripheral neuropathy, progressive vestibular loss
    - Cerebellar degeneration, Parkinson's disease
  - Generalized anxiety disorder and dysautonomias may have a indistinct starts
- Falls – gait disturbance is not part of PPPD
  - Peripheral or central neurotologic disorder
  - Cardiovascular or autonomic disorder
  - Functional gait disorder
- Constant symptoms – regardless of provocative factors
  - Accompanied by other physical complaints (fatigue, pain)
    - Somatic symptom disorder

## Key concepts in the pathophysiologic model of PPPD

- Vestibular relativity and motion priors
- Optimal control
  - Top down vs bottom up neural processing
- Misperception of motion
  - Resets movement priorities

# From bottom-up determinism to top-down relativity

## Common beliefs

- Vestibular, visual, and proprioceptive inputs are transmitted from end organs to cortex.
  - Perception of motion = conscious awareness of multi-sensory integration (deterministic).
  - Perception of motion is the end result of bottom-up transmission of multi-sensory data.
  - Basic vestibular reflexes (e.g., VOR and VSR) have fixed dynamics.
  - Perception of motion
  - Learned motor behaviors
  - Vestibular reflex actions
  - Autonomic responses
  - Emotional reactions
- } are congruent

## Emerging concepts

- Sensory inputs are highly processed and yield **context-dependent estimates** of space & motion.
- Perception of motion = conscious awareness of context-dependent estimates (**vestibular relativity**).
- **Perception of motion** and context sits at the apex of **top-down control** of movement.
- **Top-down control tunes system functioning** via optimal sets of commands that embody priorities and constraints (**cost functions and priors**).
- Each action has its own dynamics (partially linked). Perception of motion (+ context and illness) may be **dissociated** from other responses to space and motion stimuli (**normally and to our benefit**).

# From bottom-up determinism to top-down relativity

## Common beliefs

- Vestibular, visual, and proprioceptive inputs are transmitted from end organs to cortex.
  - Perception of motion = conscious awareness of multi-sensory integration (deterministic).
  - Perception of motion is the end result of bottom-up transmission of multi-sensory data.
  - Basic vestibular reflexes (e.g., VOR and VSR) have fixed dynamics.
  - Perception of motion
  - Learned motor behaviors
  - Vestibular reflex actions
  - Autonomic responses
  - Emotional reactions
- } are congruent

## Emerging concepts

- Sensory inputs are highly processed and yield **context-dependent estimates** of space & motion.
- Perception of motion = conscious awareness of context-dependent estimates (**vestibular relativity**).
- **Perception of motion** and context sits at the apex of **top-down control** of movement.
- **Top-down control tunes system functioning** via optimal sets of commands that embody priorities and constraints (**cost functions and priors**).
- Each action has its own dynamics (partially linked). Perception of motion (+ context and illness) may be **dissociated** from other responses to space and motion stimuli (**normally and to our benefit**).

# From bottom-up determinism to top-down relativity


## Common beliefs

- Vestibular, visual, and proprioceptive inputs are transmitted from end organs to cortex.
  - Perception of motion = conscious awareness of multi-sensory integration (deterministic).
  - Perception of motion is the end result of bottom-up transmission of multi-sensory data.
  - Basic vestibular reflexes (e.g., VOR and VSR) have fixed dynamics.
  - Perception of motion
  - Learned motor behaviors
  - Vestibular reflex actions
  - Autonomic responses
  - Emotional reactions
- } are congruent

## Emerging concepts

- Sensory inputs are highly processed and yield **context-dependent estimates** of space & motion.
- Perception of motion = conscious awareness of context-dependent estimates (**vestibular relativity**).
- **Perception of motion** and context sits at the apex of **top-down control** of movement.
- **Top-down control tunes system functioning** via optimal sets of commands that embody priorities and constraints (**cost functions and priors**).
- Each action has its own dynamics (partially linked). Perception of motion may be **dissociated** from other responses to space and motion stimuli (**normally and to our benefit**).


## Effects of context of external threat (normal individuals)



### Changes at height

1. Psychology – ↑ anxiety and fear
  - balance confidence ↓
  - autonomic arousal (sweating) ↑
2. Physiology – ↑ postural stiffness
  - Soleus reflexes ↑ ~10%
  - Natural sway ↓
3. **Perception** – ↑ sensation of motion
  - Forward lean, side-to-side sway ↑ 2-10%

**Perception** is an optimized solution to sensory inputs in context.  
It is relative (not absolute) and can shift dramatically (vestibular relativity).





Illusion ofvection



**The powerful effect  
of priors (experience  
& expectations) on  
perception.**

# Perception may promote recovery.

*It is a best estimate, not a direct reflection of structural integrity.*




*Perception of rotation & VOR **two days** after onset of vestibular neuritis.*





# Estimates and priors offer solutions to common ambiguities.

Qadeer Arshad et al. / Neuroscience 408 (2019) 378–387



Active versus passive motion




Translation versus tilt

# Proprioception and the predictive sensing of active self-motion

Kathleen E Cullen<sup>1,2,3,4</sup>, Omid A Zobeiri<sup>5</sup>


*Curr Opin Physiol.* 2021 April ; 20: 29–38.

Top down  
effect on  
bottom up  
processing



# Estimates and priors offer solutions to common ambiguities.


Qadeer Arshad et al. / Neuroscience 408 (2019) 378–387



Active versus passive motion



Translation versus tilt



Visual tracking


# Understanding of gravity: An essential prior

Effect of gravity on motion  
of objects in the visual field

# Watching the Effects of Gravity. Vestibular Cortex and the Neural Representation of “Visual” Gravity

Sergio Delle Monache<sup>1,2</sup>, Iole Indovina<sup>2,3</sup>, Myrka Zago<sup>2,4,5</sup>, Elena Daprati<sup>2,4,6</sup>,  
Francesco Lacquaniti<sup>2,4,6\*</sup> and Gianfranco Bosco<sup>2,4,6\*</sup>

Supplemental  
motor area



Posterior  
insular  
cortex

*Front. Integr. Neurosci.* 15:793634.  
doi: 10.3389/fnint.2021.793634

## A conceptual dilemma

- IF:
  - Perception is relative (based on context-dependent estimates)
    - and it relies on internal estimates
    - and it sometimes overrides “reality”
    - for our own good (e.g., to allow functioning with structural damage)
- THEN:
  - We need a new concept to replace our largely “bottom up” deterministic one.

## A conceptual solution

- In complex systems:
  - Internal estimates offer robust control (estimate, observe, adjust).
  - Priors drive efficiency (experience offers a library of ready-made solutions).
  - Top down (master) controller chooses from optimal solutions (shifts sets).

## Comparison of cost functions for postural stability versus fluid locomotion

Variable	Standing (low risk)	Walking smoothly
<b>Constraints (on movement)</b>	<ul style="list-style-type: none"> <li>• Sway path constrained at limits of stability.</li> <li>• Specific path not relevant.</li> </ul>	Path optimized: <ul style="list-style-type: none"> <li>• To reach target or</li> <li>• Maintain desired trajectory and</li> <li>• Avoid obstacles</li> </ul>
<b>Set point or target (spatial orientation)</b>	<ul style="list-style-type: none"> <li>• Gravity (static)</li> </ul>	<ul style="list-style-type: none"> <li>• Trajectory (dynamic)</li> </ul>
<b>Data streams and weighting (sensory inputs)</b>	<ul style="list-style-type: none"> <li>• Internal data are adequate (vestibular, proprioceptive)</li> </ul>	<ul style="list-style-type: none"> <li>• External data are required (primarily visual)</li> </ul>
<b>Operating envelope (environment)</b>	<ul style="list-style-type: none"> <li>• Support surface (narrow)</li> </ul>	<ul style="list-style-type: none"> <li>• Path and destination (wide)</li> </ul>
<b>Tolerance for error (trigger for input from controller)</b>	<ul style="list-style-type: none"> <li>• High</li> </ul>	<ul style="list-style-type: none"> <li>• Variable</li> </ul>
<b>Duration</b>	<ul style="list-style-type: none"> <li>• Not constrained</li> </ul>	<ul style="list-style-type: none"> <li>• Not constrained</li> </ul>
<b>Energy expenditure</b>	<ul style="list-style-type: none"> <li>• Minimized</li> </ul>	<ul style="list-style-type: none"> <li>• Minimized, adjusted to demand</li> <li>• Constrained by physical fitness</li> </ul>

## Comparison of cost functions for postural stability versus fluid locomotion

Variable	Standing (low risk)	Standing (high risk)	Walking smoothly
<b>Constraints (on movement)</b>	<ul style="list-style-type: none"> <li>• Sway path constrained at limits of stability.</li> <li>• Specific path not relevant.</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Sway path constrained within narrower (safer) limits.</b></li> <li>• Specific path not relevant.</li> </ul>	Path optimized: <ul style="list-style-type: none"> <li>• To reach target or</li> <li>• Maintain desired trajectory and</li> <li>• Avoid obstacles</li> </ul>
<b>Set point or target (spatial orientation)</b>	<ul style="list-style-type: none"> <li>• Gravity (static)</li> </ul>	<ul style="list-style-type: none"> <li>• Gravity (static)</li> </ul>	<ul style="list-style-type: none"> <li>• Trajectory (dynamic)</li> </ul>
<b>Data streams and weighting (sensory inputs)</b>	<ul style="list-style-type: none"> <li>• Internal data are adequate (vestibular, proprioceptive)</li> </ul>	<ul style="list-style-type: none"> <li>• Internal data are adequate (vestibular, proprioceptive)</li> <li>• <b>External data are desired (primarily visual - overweighted)</b></li> </ul>	<ul style="list-style-type: none"> <li>• External data are required (primarily visual)</li> </ul>
<b>Operating envelope (environment)</b>	<ul style="list-style-type: none"> <li>• Support surface (narrow)</li> </ul>	<ul style="list-style-type: none"> <li>• Support surface (narrow)</li> </ul>	<ul style="list-style-type: none"> <li>• Path and destination (wide)</li> </ul>
<b>Tolerance for error (trigger for input from controller)</b>	<ul style="list-style-type: none"> <li>• High</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Low</b></li> </ul>	<ul style="list-style-type: none"> <li>• Variable</li> </ul>
<b>Duration</b>	<ul style="list-style-type: none"> <li>• Not constrained</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Transient (typically momentary)</b></li> </ul>	<ul style="list-style-type: none"> <li>• Not constrained</li> </ul>
<b>Energy expenditure</b>	<ul style="list-style-type: none"> <li>• Minimized</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Constrained by physical fitness</b></li> </ul>	<ul style="list-style-type: none"> <li>• Minimized, adjusted to demand</li> <li>• Constrained by physical fitness</li> </ul>



# Transition from acute to chronic dizziness

Predictors of 6-month outcomes following acute vestibular neuritis


## High risk assessment

Acute anxiety in the form of increased body vigilance and negative illness perceptions



## Visual dependence

Over-weighting of visual cues for spatial orientation






# Misperception of motion in patients with PPPD

Perceived vs. observed motion in patients with PPPD vs. BVP vs. Control (on foam)


Patients with PPPD vs. normal controls

1. Misperceive (overestimate) postural sway
2. Misperceive (overestimate) roll/tilt of the head



# Control of stance and gait – less than optimal

Align with vertical      Direction of balance



Passive motion signal

Active motion signal

*open loop control*

*closed loop control*

During locomotion, static postural control must be inhibited or it would generate counterproductive stabilizing commands.

What if the dominant prior is high risk and estimates of motion are too high?

# Pathophysiologic model of the development of PPPD

## Precipitants

1. Vestibular crisis
2. Medical event
3. Acute anxiety

**threat**



## Acute Adaptation

1. Perception of increased motion
2. Use of high-risk postural control strategies
3. Visual-somatosensory dependence

**excessive body vigilance**



## Recovery

1. Neurotologic
2. Medical
3. Behavioral

**Chronic misperception of motion**


**Shift in priorities: from mobility to stability**

Conscious attention to postural stability over directing navigation through space

Reduced thresholds for:

- Motion detection
- Initiating closed loop feedback

↑ control effort



Overcontrolled gaze

↓ speed of gaze shifts  
↑ gaze oscillations

Visual dependence  
Vulnerability to disorienting visual stimuli


Stiffened control of posture and gait

↑ motor effort, ↓ range of stability

# Neuroimaging Indovina, et al., 2021

Consolidated images from 13 studies of PPPD and its predecessors (PPV, SMD, CSD, VID).


## Decreased cortical activity



L hemisphere

R hemisphere


## Decreased cortical volume & folding



## Decreased cortical connectivity

Convexity  
(external) view

Mid-sagittal  
(internal) view



L hemisphere

R hemisphere

AI – anterior insula; Hip – hippocampus; PI-Op – posterior insula / parietal operculum; VC – visual cortex

## Treatment of PPPD

- Three options
  1. Vestibular rehabilitation
  2. Serotonergic medications (SSRIs/SNRIs)
  3. Psychotherapy
- Often used in combination


# Physical Therapy

1. Normalize stance and gait
  - Promote relaxed stance, normal weight distribution, reshape functional changes
2. Improve tolerance for own motion
  - Head/eye movement ► body movement – habituation, not compensation
3. Improve tolerance for visual stimuli
  - Complex patterns, moving stimuli – This can be the most difficult rehab task.

*Pacing and persistence are the keys to success.*

*Make it boring!*

## Sertraline with and without CBT



8 open trials + 1 randomized trial (N>500)

- All 6 SSRIs – fluoxetine, sertraline, paroxetine, (es)citalopram, fluvoxamine
- 2 of 6 SNRIs – venlafaxine, milnacipran
- PPPD-type dizziness
- Not mediated by anxiety, depression

## Medication dosing strategies

	<b>Starting dose (1-2 weeks)</b>	<b>Titration increment (2-4 week intervals)</b>	<b>Final dose range (maintenance therapy 1+ years)</b>
Sertraline	25 mg daily	25-50 mg	50-200 mg daily
Escitalopram	5 mg daily	5 mg	10-20 mg daily
Venlafaxine XR	37.5 mg daily	37.5-75 mg	75-225 mg daily



# Psychotherapy

## Randomized controlled trials

- Cognitive Behavior Therapy (CBT)
- Acceptance and Commitment Therapy (ACT)

## Goals

1. Reduce body vigilance
2. Reduce negative illness perceptions
3. Reduce anticipatory anxiety and avoidance of provocative stimuli.

Treatments for PPPD - comparison of outcomes		Pre-Tx DHI	Post-Tx DHI	Change MCID=18
<b><u>Vestibular therapy</u></b>				
<i>Nada, 2019</i>	6 weeks individualized exercises (N=60)	58	36	<b>22</b>
<i>Teh, 2022</i>	12 weeks in-clinic (N=15) vs. at-home (N=15)	50 (all patients)	34 (all patients)	<b>18 (clinic)</b> 14 (home)
<i>Herdman, 2022 (INVEST)</i>	6 sessions psychologically-informed (N=20) vs standard VRT (N=20)	64 (INVEST) 65 (standard)	37 (INVEST) 49 (standard)	<b>27 (INVEST)</b> 16 (standard)
<b><u>Medication</u></b>				
<i>Yu, 2018</i>	8 weeks, sertraline alone (N=45) vs. sertraline + CBT (N=46)	54 (sert alone) 54 (sert + CBT)	26 (sert alone) 15 (sert + CBT)	<b>28 (sert alone)</b> <b>39 (sert + CBT)</b>
<i>Min, 2021</i>	Chart review (N=197) -- SSRIs (escitalopram) + BZD (clonazepam)	50	65% much/very much improved	
<b><u>Psychotherapy</u></b>				
<i>Waterston, 2022</i>	Chart review (N=150) -- CBT	50	24	<b>26</b>
<i>Kuwabara, 2020</i>	6 wks, Acceptance and Commitment Therapy + VRT (N=27)	49	26 (at 6 months)	<b>23</b>

## Emerging therapeutics – *not ready for prime time*

### Neuromodulation – early trials

- Non-invasive vagal nerve stimulation (nVNS)
  - 4 weeks – positive effect on dizziness, postural sway, quality of life
- Transcranial direct current stimulation (tDCS) – active vs. sham treatment
  - 15 sessions over 3 weeks – no benefit
- Repetitive transcranial magnetic stimulation (rTMS) – active vs. sham treatment
  - 4 weeks, daily sessions – results forthcoming


## ICVD definition of Mal de débarquement syndrome (MdDS)

- A. Non-spinning vertigo characterized by an oscillatory perception ('rocking,' 'bobbing,' or 'swaying') present continuously or for most of the day.
- B. Onset occurs within 48 hours after the end of exposure to passive motion.
- C. Symptoms temporarily reduce with exposure to passive motion.
- D. Symptoms continue for >48 hours.
  - D.0. MdDS in evolution – symptoms are ongoing, but the observation period has been less than 1 month
  - D.1 Transient MdDS – symptoms resolve at or before 1 month and the observation period extends at least to the resolution point
  - D.2 Persistent MdDS – symptoms last for more than 1 month
- E. Symptoms are not better accounted for by another disease or disorder.


Frequency of postural sway in patients with MdDS

Sway (perceived and observed) is thought to reflect entrainment of precipitating motion.

A necessary prior that fails to reset.



## MdDS – hypermetabolism of the entorhinal cortex



**Entorhinal cortex**  
Grid cells  
(Spatial location, heading  
and speed)




Left hippocampus  
(Egocentric spatial  
navigation)

## Treatment of MdDS – usually partial benefit

- Patient education
- Medications (clinical experience, online patient survey)
  - SSRIs and SNRIs – especially venlafaxine (same dosing as for PPPD)
  - Benzodiazepines – standing dose or prn
- Velocity storage reprogramming – “Mount Sinai (Dai) protocol”
- Physical therapy – routine vestibular rehabilitation does not seem to be effective
- Psychotherapy – for psychiatric comorbidity

# Treatment of MdDS – neuromodulation (still experimental)

*Transcranial magnetic stimulation over the dorsolateral prefrontal cortex*





# Chronic dizziness as part of somatic symptom disorder


## Somatic symptom disorder (DSM-5 definition)

- A. 1+ somatic symptoms that are distressing or disrupt daily life
  - B. Illness-related thoughts, feelings, behaviors
    1. Thoughts about seriousness of symptoms
    2. High level of worry about symptoms (esp. about consequences)
    3. Aberrant health-seeking behaviors (too much or too little)
  - C. Symptoms present for 6+ months
- Mechanism is unknown – central sensitization + altered cognitions & behaviors??
  - Chronic dizziness often co-exists with chronic pain (headache, fibromyalgia), chronic fatigue, and chronic non-specific cognitive complaints (brain fog).
    - May resemble PPPD (meeting criteria A-C)
    - Responds poorly to outpatient treatment
    - Clinical experience strongly supports multi-disciplinary rehabilitation programs
      - Intensive outpatient or inpatient – 2-4 weeks (pain rehab programs)

## Conclusions


- PPPD is the most common cause of chronic vestibular and balance symptoms
  - One of the top three diagnoses in neuro-otology (with BPPV and vestibular migraine)
- Established diagnostic criteria
  - ICVD – Bárány Society; ICD-11 – World Health Organization
- Pathophysiologic mechanisms
  - Misperception of motion drives a top-down shift from smooth locomotion to postural stability
- Treatment
  - Individualized vestibular rehabilitation
  - Serotonergic medication (SSRIs and SNRIs)
  - Cognitive behavior therapy

} *Sequentially or  
in combination*




## Conclusions

- MdDS is often overlooked or misdiagnosed
  - Prevalence of transient disembarkment symptoms is common, prevalence of MdDS ??
- Established diagnostic criteria
  - ICVD – Bárány Society
- Pathophysiologic mechanisms
  - Entrainment of inciting motion stimulus
- Treatment
  - Specialized vestibular reprogramming
  - SSRIs/SNRIs or benzodiazepines



## Conclusions

- Somatic symptom disorder is often overlooked
  - Focus on individual symptoms rather than overall somatic burden; prevalence ??
- Established diagnostic criteria
  - DSM-5
- Pathophysiologic mechanisms (unknown)
  - Central sensitization and aberrant illness-related anxieties, beliefs, and behaviors ??
- Treatment
  - Multi-disciplinary rehab programs





Thank you for your attention.

Questions & Discussion



[Staab.Jeffrey@mayo.edu](mailto:Staab.Jeffrey@mayo.edu)

## References – citations in this presentation and additional resources

1. Adamec I, Meaški SJ, Skorić MK, Jažić K, Crnošija L, Milivojević I, Habek M. Persistent postural-perceptual dizziness: Clinical and neurophysiological study. *J Clin Neurosci* 2020;72:26-30.
2. Cousins S, Kaski D, Cutfield N, Seemungal B, Golding JF, Gresty M, Glasauer S, Bronstein AM. Vestibular perception following acute unilateral vestibular lesions. *PLoS One*. 2013 May 9;8(5):e61862.
3. Cullen KE. Vestibular processing during natural self-motion: implications for perception and action. *Nature Rev Neurosci*. 2019;20:348-363.
4. Cullen KE, Zobiari, OA. Proprioception and the predictive processing of active motion. *Curr Opin Physiol*. 2021;20:29-38.
5. Eren OE, Filippopoulos F, Sönmez K, Möhwald K, Straube A, Schöberl F. Non-invasive vagus nerve stimulation significantly improves quality of life in patients with persistent postural-perceptual dizziness. *J Neurol*. 2018 Oct;265(Suppl 1):63-69.
6. Godemann F, Siefert K, Hantschke-Bruggemann M, et al. What accounts for vertigo one year after neuritis vestibularis—anxiety or a dysfunctional vestibular organ? *J Psychiatr Res* 2005;39:529–34.
7. Graham. MK, Staab JP, Lohse CM, et al. A comparison of dizziness handicap inventory scores by categories of vestibular diagnoses. *Otol Neurotol* 2021;42(1):129-36.

## References

8. Habs M, Strobl R, Grill E, Dieterich M, Becker-Bense S. Primary or secondary chronic functional dizziness: does it make a difference? A DizzyReg study in 356 patients. *J Neurol* 2020;267(Suppl 1):212–222.
9. Heinrichs N, Edler C, Eskens S, et al. Predicting continued dizziness after an acute peripheral vestibular disorder. *Psychosom Med* 2017;69:700–7.
10. Im JJ, Na S, Kang S, Jeong H, Lee E-S, Lee T-K, Ahn W-Y, Chung Y-A and Song I-U. A Randomized, Double-Blind, Sham-Controlled Trial of Transcranial Direct Current Stimulation for the Treatment of Persistent Postural-Perceptual Dizziness (PPPD). *Front. Neurol.* 2020;13:868976.
11. Kabaya K, Tamai H, Okajima A, et al. Presence of exacerbating factors of persistent perceptual-postural dizziness in patients with vestibular symptoms at initial presentation. *Laryngoscope Investig Otolaryngol* 2022;7(2):499-505.
12. Kim HJ, Lee JO, Choi JY, Kim J. Etiologic distribution of dizziness and vertigo in a referral-based dizziness clinic in South Korea. *J Neurol*, 2020;267:2252–2259.
13. Kuwabara J, Kondo M, Kabaya K, Watanabe W, Shiraishi N, Sakai M, Toshishige Y, Ino K, Nakayama M, Iwasaki S, Akechi T. Acceptance and commitment therapy combined with vestibular rehabilitation for persistent postural-perceptual dizziness: A pilot study. *Am J Otolaryngol.* 2020;41:102609.
14. Min S, Kim JS, Park HY. Predictors of treatment response to pharmacotherapy in patients with persistent postural-perceptual dizziness. *J Neurol.* 2021 Jul;268(7):2523-2532. doi: 10.1007/s00415-021-10427-7

## References

15. Nada EH, Ibraheem OA, Hassaan MR (2019). Vestibular rehabilitation therapy outcomes in patients with persistent postural-perceptual dizziness. *Ann Otol Rhinol Laryngol*, 128(4), 323-329.
16. San Pedro Murillo E, Bancroft MJ, Koochi N, Castro P, Kaski D. Postural misperception: a biomarker for persistent postural-perceptual dizziness. *J Neurol Neurosurg Psychiatry* 2023;94(2):165-166.
17. Schniepp R, Wuehr M, Huth S. Gait characteristics of patients with phobic postural vertigo: effects of fear of falling, attention, and visual input. *J Neurol*, 2014;261:738–46.
18. Staab JP. Persistent postural-perceptual dizziness: Review and update on key mechanisms of the most common functional neuro-otologic disorder. *Neurol Clin*. 2023;41(4):647-664. doi: 10.1016/j.ncl.2023.04.003.
19. Staab JP, Eckhardt-Henn A, Horii A, Jacob R, Strupp M, Brandt T, Bronstein A. Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Barany Society. *J Vestib Res*, 2017;27:191-208.
20. Staibano P, Lelli D, Tse D. A retrospective analysis of two tertiary care dizziness clinics: a multidisciplinary chronic dizziness clinic and an acute dizziness clinic. *J Otolaryngol Head Neck Surg*. 2019;48:11.
21. Takakusaki K. Functional neuroanatomy for posture and gait control. *J Mov Disord* 2017;10(1):1-17.
22. Trinidad, A., Cabreira, V., Kaski, D. et al. Treatment of Persistent Postural-Perceptual Dizziness (PPPD). *Curr Treat Options Neurol* 2023;25:281–306. <https://doi.org/10.1007/s11940-023-00761-8>



## References

23. Trinidad A, Harman P, Stone J, et al. Assessment of potential risk factors for the development of persistent postural-perceptual dizziness: A case-control pilot study. *Front Neurol* 2021;11:601883.
24. Wang A, Fleischman KM, Kawai K, Corcoran M, Brodsky JR. Persistent Postural-Perceptual Dizziness in Children and Adolescents. *Otol Neurotol*. 2021 Sep 1;42(8):e1093-e1100.
25. World Health Organization. ICD-11 for Mortality and Morbidity Statistics. AB32.0 Persistent Postural-Perceptual Dizziness. <https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/2005792829?view=G0>.
26. Wuehr M, Pradhan C, Novozhilov S, et al. Inadequate interaction between open- and closed-loop postural control in phobic postural vertigo. *J Neurol*. 2013;260(5):1314-23.
27. Wurthmann S, Holle D, Obermann M, et al. Reduced vestibular perception thresholds in persistent postural-perceptual dizziness - a cross-sectional study. *BMC Neurol*. 2021;21:394.
28. Xue H, Chong Y, Jiang ZD, Liu ZL, Ding L, Yang SL, Wang L, Xiang WP (2018). Etiological analysis on patients with vertigo or dizziness. *Zhonghua Yi Xue Za Zhi*, 98(16), 1227-1230.
29. Yu Y-C, Xue H, Zhang Y-X, Zhou J. Cognitive behavior therapy as augmentation for sertraline in treating patients with persistent postural-perceptual dizziness. *BioMed Research International*. 2018, Article ID 8518631
30. Yagi C, Morita Y, Kitazawa M, et al. Head roll-tilt subjective visual vertical test in the diagnosis of persistent postural-perceptual dizziness. *Otol Neurotol* 2021;42(10):e1618-24.

# **Advances in Evaluation and Management of Psychogenic Nonepileptic Seizures**

W. Curt LaFrance Jr., MD, MPH, FAAN,  
FANPA, DFAPA

# **Differential Diagnosis and Potential Pitfalls in the Evaluation of Functional Neurological Disorders**

Sara A Finkelstein, MD, FRCPC

# Differential Diagnosis and Potential Pitfalls in the Evaluation of Functional Neurological Disorder

INS Conference  
Nov 3, 2023

Sara Finkelstein, MD MSc FRCPC

Functional Neurological Disorder Unit, Dept. of Neurology  
Massachusetts General Hospital, Boston, MA  
[safinkelstein@mgh.harvard.edu](mailto:safinkelstein@mgh.harvard.edu)



# Objectives


Develop a differential diagnosis for functional neurological disorder.

Describe diagnostic pitfalls to be aware of when considering a diagnosis of functional neurological disorder.

Develop a rational diagnostic workup for functional neurological disorder.



# What is FND?



- A neuropsychiatric disorder in which neurological symptoms are caused by a problem of brain networks
- Diagnosis based on **POSITIVE SIGNS** or **SEMIOLOGICAL FEATURES** typical of FND:

showing **INCONSISTENCY / REVERSIBILITY** of symptoms

- *No longer a diagnosis of exclusion*
- *No longer need stressor preceding to make diagnosis*



# General pitfalls to be aware of

---

1

Excluding diagnosis based on demographic factors

2

Including/excluding diagnosis based on personality factors

3

Basing diagnosis on history of psychiatric comorbidity

4

Basing diagnosis on preceding stressor




## Vignette: 27F with weakness

- Walking into work when started having trouble moving and feeling her legs, worse on right
- Progressive worsening over 3 hours, to a point where she was having trouble moving and feeling both her arms as well as legs



# Exam in clinic several weeks later

- In wheelchair
- Motor: UE mild **global weakness**. **LE R 2/5, L 3/5** in flexors and extensors
- Sensation: Decreased to pinprick arms and legs
- Gait: **Able to ambulate around the room without aid**. Slow, wide-based, hesitant.
- **Positive Hoover sign** and **hip abductor sign** on right




# Limb Weakness

# Drift without pronation

*So-so reliability*

**Fig. 18.5.** Drift without pronation sign: **(A)** hand drift and pronation in organic pyramidal arm weakness; **(B)** hand drift without pronation in functional arm weakness.



*From Stone and Aybek, Handbook of Clinical Neurology Ch. 18, 2016*

# Hip Abductor sign

*High reliability*

# Other useful signs



Global weakness

*So-so reliability*



Collapsing weakness

*Good reliability*



Motor inconsistency

- < 3/5 strength supine but able to walk
- Able to stand on tiptoes or heels, but poor ankle strength when supine
- “Pseudo waxy flexibility” - unable to make antigravity movement but can hold limb antigravity when positioned there


*So-so reliability*

## 2 Cases




- 59M with dense right hemiplegia
  - PMHx: MI
  - Strength in leg 2/5, arm 1-2/5
  - Hoover sign positive
  - Able to reach for water with weak hand when offered
  - Unaware of this discrepancy
- 52F with dense right hemiplegia, mild right facial droop
  - PMHx: non-ischemic cardiomyopathy, polymorphic VT with ICD
  - Strength 0/5 arm and leg, decreased sensation leg
  - Able to bear weight, positive Hoover sign

False positive Hoover sign and reversibility of weakness reported in Supplementary Motor Area (SMA) stroke




Mathew et al 2018 *Stroke*



Mohebi et al 2019 *J Neurology*



CLINICAL VIGNETTE |  **Free Access**

## **False Positive Hoover's Sign in Apraxia**

Tommaso Ercoli MD , Jon Stone MB, ChB, FRCP, PhD


- 90F with 5 year history of not being to move left arm and leg properly
- Able to walk and use arm better with distraction
- Positive Hoover and hip abductor signs
- Marked rigidity, dystonia, and apraxia of right arm and leg
- Diagnosed with corticobasal syndrome



# It can always localize to the thalamus...


---

- 76F with postural instability
- Sitting relatively stable, unable to stand unassisted
- Lots of swaying back and forth while standing, with collapse when support withdrawn
- Strength and appendicular coordination testing showed mild dysmetria in left hand only



# What about sensory symptoms?

- Midline splitting or splitting of vibration sense have low discriminatory power
- “Non-anatomic” sensory distributions (e.g., glove pattern on single hand) can be found in small cortical stroke



# Multiple Sclerosis and FND

Journal of Neurology (2022) 269:654–663


<https://doi.org/10.1007/s00415-021-10436-6>

REVIEW

## Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap

Dennis Walzl<sup>1</sup>  · Andrew J. Solomon<sup>2</sup>  · Jon Stone<sup>1</sup> 

MS and FND  
Overlap



## MS and FND Overlap

Front. Neurol., 11 April 2023

Sec. Multiple Sclerosis and Neuroimmunology

Volume 14 - 2023 | <https://doi.org/10.3389/fneur.2023.1077838>

# Functional neurological symptoms are a frequent and relevant comorbidity in patients with multiple sclerosis



Katya Piliavska<sup>1\*</sup>



Michael Dantlgraber<sup>2</sup>



Christian Dettmers<sup>1,3</sup>



Michael Jöbges<sup>1,3</sup>



Joachim Liepert<sup>1,4</sup>



Roger Schmidt<sup>1,5</sup>

# Functional Limb Weakness Diagnostic Pitfalls



Over-reliance on mildly positive or single rule-in sign

Overlooking minor concomitant symptoms that are not functional

Bias due to psychiatric history or stressor preceding symptom onset

Failure to consider pain




## Approach to Diagnostic Testing:

- 1) Stroke work-up is appropriate for sudden onset neurological symptoms **of unknown etiology**
- 2) MRI brain + spine typically appropriate for functional limb weakness workup

# Alteration of Consciousness or Awareness





Functional Seizures:  
Diagnosis is based on  
typical semiological  
features

*See Espay et al. JAMA Neurology 2018; Aybek and Perez BMJ 2022*

# Exam signs with good reliability for: functional seizures



Eye closure/resistance to opening



Duration > 2 minutes



Stopping and starting



Asynchronous limb movements



Maintained awareness  
during a generalized event



Ictal weeping

# Unhelpful or Common to Both



Tongue biting  
& incontinence



Aura or  
post-ictal  
confusion



Injury (bumps,  
bruises)



Sympathetic  
activation or  
dissociation




Attack out  
of (non-EEG  
confirmed)  
'sleep'



No  
witnesses

# Not all non-epileptic events are functional seizures




EEG

- Normal variants can be mistaken for abnormalities - e.g., wicket spikes,
- Non-specific EEG changes common in patients with functional seizures
- Deep seizure foci may not demonstrate scalp EEG changes

# 36F with episodes of déjà vu


---

- Disoriented for a few seconds
- May have a brief visual hallucination
- Other associated symptoms have variably included: tingling, fatigue, feeling like she is underwater or heavy, feeling limp, presyncope, photophobia, difficulty opening her eyes
- Can respond throughout, doesn't always remember episode well
- Afterwards, gets a throbbing, moderate-severe headache, associated with photophobia
- Other PMHx: migraine, panic attacks, PTSD, ADHD



# Differential diagnosis?

Is this a functional seizure, migraine with complex aura, dissociation related to PTSD or anxiety diagnosis?



A combination of some of the above?

DDx:  
Autonomic  
or  
dissociative  
symptoms

- Can precede epileptic or functional seizures
- PTSD and anxiety/panic can have a high degree of sympathetic activation or dissociation
- Can cause 'staring spells'/low responsiveness, paresthesias, dizziness, cognitive symptoms (attention, memory)
- Might not have an associated emotional valence (e.g., 'panic without panic')





# Possible interactions between FND and migraine

- Migraine/aura as a somatic trigger for FND symptoms
- Migraine causing some dissociation or fatigue, in which FND symptoms are more likely to occur
- Migraine and FND tend to occur in similar demographics and appear to co-occur at elevated rates (Khoja et al 2020)
- Migraine worsening FND symptoms that are already present





## Approach to Diagnostic Testing:

- 1) MRI and EEG generally appropriate for seizure-like episodes
- 2) Importance of capturing event on EEG depends on how consistent semiology is with functional seizure

Failure to  
consider to the  
psychiatric  
differential...

Incomplete diagnosis: not factoring in active psychiatric concerns into a biopsychosocial formulation for the patient

Wrong diagnosis: psychiatric disorders can mimic FND

# Movement Disorders

# Video Vignette:

55yo M, otherwise healthy,  
presenting with sudden  
onset severe tremor in the  
hands

# Tremor – Potential Pitfalls



- Amplitude can vary in PD, ET, and functional tremor
- Putting an overemphasis on importance of stress worsening symptoms: most tremor types get worse with stress
- Irregular amplitude and frequency can be seen with dystonic tremor

Video Vignette: 24yo M with new onset problems walking, no history of trauma

# Video vignette: Patient with reversible foot dystonia



Video vignette: 40M with bizarre gait

# Functional Gait Disorder – Potential Pitfalls



No single pathognomonic pattern

Bizarre ≠ functional

Dystonic gait can improve with alternate motor pattern or be inconsistent over time

# Functional Dystonia

Fixed dystonic posturing, with plantar flexion & inversion of foot



Fixed dystonic posturing, with toe curling

Functional hand dystonia, with preserved pincer function



Complex regional pain syndrome and functional neurological disorders: time for reconciliation

Stoyan Popkirov,<sup>1</sup> Ingrid Hoeritzauer,<sup>2</sup> Lesley Colvin,<sup>3</sup> Alan J Carson,<sup>2</sup> Jon Stone<sup>2</sup>

*J Neurol Neurosurg Psychiatry* 2018;**0**:1–7

Schmerler & Espay, 2016  
Popkirov et al., 2018  
Frucht et al., 2021

# Dystonia: Features in favor of FND

- Abrupt onset
- Fixed posture at onset
- Pain in affected body part
- Resistance to passive movements
- Varying in distribution & severity spontaneously



# Functional Dystonia - Potential Pitfalls

Several features can be common to both functional and other causes of dystonia:



- Change with alternate motor pattern
- Abnormal posturing
- Associated tremor
- Variability





Viewpoint |  Open Access |   

## Rapid Onset Functional Tic-Like Behaviors in Young Females During the COVID-19 Pandemic

Tamara Pringsheim MD , Christos Ganos MD, PhD, Joseph F. McGuire Phd, Tammy Hedderly MBBS, Douglas Woods Phd, Donald L. Gilbert MD, John Piacentini PhD ... [See all authors](#) 

First published: 13 August 2021 | <https://doi.org/10.1002/mds.28778> | Citations: 57



# Functional Tics: Pitfalls

- Several features can be common to both functional tics and other causes of tics:
  - Triggered by stimulus
  - Warning/build-up beforehand
  - Suggestibility/worsening with attention
  - Suppressibility



# Vignette: 72F with parkinsonism

---

- 6 years ago developed tremor in her leg, shuffling gait
- Initially seemed to respond to Sinemet, followed by poor response with escalating doses
- Now has severe symptoms of fatigue, slackness of lower facial muscles, drooling, difficulty walking, shuffling, leg tremor
- 'Off' symptoms occur very rapidly



# Vignette: 72F with parkinsonism

---

- Initially noted to have no parkinsonism other than slight rigidity at one wrist
- On repeat exam during 'off' period, noted:
  - Increased respiratory rate
  - Blank stare, slackness of lower face/jaw – muscles still strong to activation
  - No increase in rigidity or bradykinesia
  - Tremor alternating between left and right leg that was distractible
  - Gait slow, short stride length, normal turn, no freezing
  - Negative pullback test

# FND symptoms may precede onset of or co-occur with Parkinson's disease

## Functional neurological disorders in Parkinson disease

---

Wissel BD, et al. *J Neurol Neurosurg Psychiatry* 2018;**89**:566–571. doi:10.1136/jnnp-2017-317378

## Functional Motor Symptoms in Parkinson's Disease and Functional Parkinsonism: A Systematic Review

Marine Ambar Akkaoui, M.D., Pierre A. Geoffroy, M.D., Ph.D., Emmanuel Roze, M.D., Ph.D., Bertrand Degos, M.D., Ph.D., Béatrice Garcin, M.D., Ph.D.

*J Neuropsychiatry Clin Neurosci* 32:1, Winter 2020



# Functional Parkinsonism – Potential Pitfalls

- If rest tremor present, look for other signs of functional tremor
- Rigidity in FND due to paratonia and should improve with distraction
- Movements may be slow in both PD and FND – look for decrement
- Gait may be slow, difficult to initiate for both

# Approach to Diagnostic Testing:




- 1) Many types of movement disorders rest upon a clinical diagnosis
- 2) Consider DAT-scan for parkinsonism
- 3) Diagnosis requires a high degree of familiarity with broad spectrum of MDs

Cognitive symptoms

# Vignette: 63F with worsening memory

---

- Word-finding difficulty and forgets what she is saying in the middle of a sentence
- Reports having to ask her daughter to repeat things
- Trouble with concentration
- Husband died last year
- Sleeping poorly – waking up at 4 am and can't get back to sleep
- Eating less



# Depression



Can have a number of symptoms that overlap with FND



Fatigue, pain, problems with sleep



Cognitive symptoms can include memory and attention problems

# Vignette: 21M with cognitive concerns

---

- Struggling more in school - A/Bs to barely passing
- 3 month history of high degree of somatic symptoms including paresthesias, feeling like his veins were very prominent, pain reported in jaw & right elbow, some blurring of vision, sensation of difficulty swallowing
- Reports some worsening of mood; affect blunted on exam
- Parents note he has become socially withdrawn and isolated





# Psychotic Spectrum Disorders

- Rarely overlap with FND
- However, psychotic prodrome can often have a number of overlap features with FND:
  - Unusual body sensations or sensory abnormalities
  - Somatic preoccupations
  - Cognitive difficulties
  - Problems with communication
  - Impaired stress tolerance

# Approach to Diagnostic Testing:



- 1) Consider MRI brain for new / worsening cognitive symptoms – particularly if middle-late age
- 2) Neuropsychological testing can be helpful in interpreting cognitive changes in context of psychiatric symptoms, baseline IQ, etc.
- 3) Consider possible psychiatric differential – engage psychiatry/neuropsychiatry colleagues as needed

# Take Home Messages

- Diagnosis of FND is based on rule-in signs
- Signs for functional limb weakness can rarely have false positives
- There are both neurological and psychiatric considerations for DDX of periods of altered awareness and cognitive symptoms
- Be aware of overlap of functional movement disorder features with other MD diagnoses
- Diagnostic testing will depend on FND symptom subtype of degree of concern for alternative etiologies based on exam

Thank you! Questions?  
safinkelstein@mgh.harvard.edu

Further reference: Finkelstein and Popkirov 2023 *Neurologic Clinics*

# **Managing Functional Neurological Disorders in the Emergency Department**

Barbara A Dworetzky, MD, FAAN

# FUNCTIONAL NEUROLOGIC DISORDER AND THE EMERGENCY DEPARTMENT (ED)



## Barbara Dworetzky, MD

Professor of Neurology, Harvard Medical School

Chief, Epilepsy

Director, Bromfield Epilepsy Center

Program Dir., Clinical Neurophysiology Fellowship

Brigham and Women's Hospital/MGB



# Brigham & Women's Hospital



Building for Transformation of Medicine

 Mass General Brigham



Peter Bent Brigham Hospital



Harvard Medical School, Boston

# Disclosures

- Founding member; President-Elect, Functional Neurological Disorders Society (FNDS)
- PAB, Epilepsy Foundation New England





# Functional disorders are ubiquitous...

- GI: IBS
- Urology: OAB
- Rheumatology: FBM
- Infectious disease:CFS
- Immunology: multiple chemical sensitivities
- \*Cardiology: Atypical CP, syncope
- \*Pulmonary: SOB
- \*ENT: Globus
- Gyn: pelvic pain
- Ophthalmology: blindness
- Neuro: seizures/attacks; weakness, movement, sensory, cognitive/speech problems; dizziness**

**FND**

# The Burden is High...

- **FND** Health Care Utilization (HCU) is very costly (meds, tests, admissions, amb, **ED, ICU visits**)<sup>1,2,3</sup>, ~1.2 bill. (adults); 88 mill.(peds)<sup>4</sup>
- Lower rates of employment<sup>5</sup>
- ↓QOL (<= other neuro disorders)<sup>6</sup>
- Stigma worse <sup>7</sup>
- Caregiver burden similar <sup>8,9</sup>
- **Increased risk of injury,<sup>10</sup> death (SMR 2.5x gen. pop)<sup>11-13</sup>**

1. Martin et al, *Seizure* 1998; 2. Seneviratne et al, *Epilepsia* 2019; 3. O'Mahony et al, *Neurology* 2023; 4. Stephen et al, *JAMA* 2021; 5. Jennum et al, *E and B*, 2019; 6. Szaflarski and Szaflarski, *Epilepsy and Beh* 2004; 7. Robson et al, *Seizure* 2018; 8. Karakis et al, *Seizure* 2014; 9. Tsamakis et al, *Epileptic Dis*, 2023; 10. Moreira et al, *Epilepsia* 2023; 11. Nightscales et al, *Neurology* 2020; 12. LeZhang et al, *JNNP*, 2022; 13. Gelauff et al, *Brain*, 2019;

# Prognosis is generally unfavorable\* Gelauff, Stone 2016

- 71-75% adults w/FND continue to have symptoms<sup>1-3</sup>
- 56% are on disability
- Only 18% adults become sx free, able to work<sup>3</sup>
- Comorbid neuro/psych d/o,<sup>4,5</sup> receiving state disability,<sup>6</sup> social deprivation,<sup>7</sup> other somatic sx? → worse outcomes
- Children more likely resolve FND<sup>8</sup> but not school and family dysfunction<sup>9</sup>

1. Reuber, Pukrop, Bauer et al, Ann Neurol 2003; 2. Lancman, Brotherton et al, Seizure 1993; 3. Walczak, Papcostas et al, Epilepsia 1995; 4. Meierkord et al., 1991; 5. Gelauff, Stone 2016; 6. Duncan et al, 2014; 7. Goldstein et al, Epilepsia 2019; 8. Raper et al, 2019; 9. Dworetzky, Epilepsy Currents, 2015.

# Why are outcomes poor?\*

1. Rawlings, Reuber 2018; Barnett et al, 2022

- Health care providers are confused, fearful, challenged, avoidant<sup>1,2</sup>
- ?Clinicians don't believe it is a real disorder; Lack of: follow up, ownership of care?
  - Continue to order consults, tests, medications adding to confusion
  - FND is often not documented or considered in the medical record
- Disorder begins years before "diagnosis" (long delay)
- Lack of funding to study it? No drugs to treat it → No pharma \$\$
- Limited evidence-based treatment (starting to change 😊)
- Secondary gain (perpetuating factors)
- ED and Internists → **"biased to malingering"** as cause *Kilic et al, 2021*

## • Repeated ED visits are common w/ FND

- **Decreased ED reattendance linked to:**
  - Documented FND in chart (p<.004)
  - Referral to treatment (p<.04)
  - Outpt neuro follow up (p<.001)

*Williams et al, To emergency room and back: circular healthcare pathways for acute FND J. Neurolog Sci, 2022*

**\*We don't know why but FND has been neglected and we need to do better!**


# Let's look at us in the ED...

Video is courtesy of Bernd Pohlmann

Video demonstrating what we regularly have been doing in the ED with patients with FND

# Communication Pitfalls

- Only explaining what they don't have
- Attributing symptoms to stress/psych
- Implying it is 'all in their head', fake ("not real")
- Reporting normal test results as evidence of the diagnosis
- Blaming the patient
- Not believing symptoms\*
- Not inviting 2-way communication\*
- Not developing rapport\*
- Not allowing follow-up




\***Trauma-Informed-Care (TIC)** : Safety, choice, collaboration, trustworthiness, empowerment





International Parkinson and  
Movement Disorder Society

# Curriculae have been lacking...



American Board of Psychiatry and Neurology, Inc.  
A Member Board of the American Board of Medical Specialties (ABMS)



American Academy  
of Pediatrics  
DEDICATED TO THE HEALTH OF ALL CHILDREN™



Accreditation Council for  
Graduate Medical Education



AMERICAN  
NEUROPSYCHIATRIC  
ASSOCIATION



AMERICAN  
EPILEPSY  
SOCIETY

# except as a neurological differential diagnosis...



Neurol Clin ■ (2023) ■-■  
<https://doi.org/10.1016/j.ncl.2023.02.007>  
0733-8619/23/© 2023 Elsevier Inc. All rights reserved.

neurologic.theclinics.com



# Functional Neurological Disorder

Definition from *Hallett et al, Lancet, 2022*:

Clinical syndrome consisting of symptoms and signs of **genuinely experienced** alterations in motor, sensory, or cognitive performance which are **distressing or impairing**, and manifest as one or more patterns of deficits that are consistent predominantly with **dysfunction of the nervous system** and show **variability in performance** within the same task or between different tasks.

[nature](#) > [nature reviews neurology](#) > [perspectives](#) > article

Perspective | [Published: 16 February 2023](#)

## Why functional neurological disorder is not feigning or malingering

[Mark J. Edwards](#) , [Mahinda Yogarajah](#) & [Jon Stone](#)

[Nature Reviews Neurology](#) **19**, 246–256 (2023) | [Cite this article](#)

**FND is stigmatized** because it is commonly **confused with feigning**. The problem lies in the voluntary motor system where performance may change with attention. It is **not fake**, and **we do great harm** to patients with implicit or explicit bias revealing beliefs which are incorrect and not based on the most up to date evidence.

# Objectives

1. Know how to diagnose FND using positive signs
2. Be aware of the pitfalls of FND in the ED
3. Discuss initial management of FND in the ED

# Acute Neuro Symptoms to the ED

*Merkler et al, JNNP 2016; Moeller et al, 2008; Walzl, Carson, Stone J Neurol 2019; Lange et al, 2011; Williams et al, To the emergency room and back again: circular healthcare pathways for acute FND, J Neurolog Sci, 2022. Mastrangelo, Baglioni 2021*



- ~15% of Adult ED visits are neurological, ~ 30% pediatric visits
- Most common: **HA, Stroke/TIA, Syncope/Seizure/SE, FND, decompensation of neuro disorder, dizziness, weakness, sensory loss,  $\Delta$ MS**
- **FND** often presents **acutely, for the first time**, to the ED;
- But not infrequently has **repeat presentations** to ED including for other functional symptoms making it quite challenging and it is **often misdiagnosed as another neurological disorder**
- ***Nontraumatic HA common comorbidity in FND:** worst HA of life, LOC or AMS, seizure, lost vision, vomiting, prolonged, sudden/severe at onset, infection, pregnant, immune suppressed, age>50, AC, substance use, papilledema, meningismus, fever*

# Pitfalls: our biases

- Prediction based on RF (premature closure\*\*, confirmation bias)
- Short circuit of history and rapport
- Believing a test will help with diagnosis
- Test and treat to avoid medicolegal consequences


*Our brain can anchor on wrong diagnosis framed by risk factors and can mislead us (not suspecting correct diagnosis)*

**Be nonjudgmental, open minded**



*"It's really quite simple: every time you decide something without having a good reason, you jump to Conclusions whether you like it or not. It's such an easy trip to make that I've been here hundreds of times."*

# Risk of Misdiagnosis in ED



# FND presenting to the ED

- Prevalence 0.4 – 4% (likely an **underestimate**)<sup>1</sup>, high return rate<sup>2</sup>
- 9% acute neuro admits;<sup>3</sup> 13% ED neuro consults<sup>4</sup>
- 12% of “strokes” to ED are FND<sup>5</sup>
- 15% of FND sz 1<sup>st</sup> present to ED<sup>1</sup> and ~11% sz in ED=FND<sup>6</sup>
- 25% “SE” in ED is FND<sup>7</sup>
- 1.4% Functional movement disorder<sup>8</sup>




# History suggestive of FND

*"Listen to your patient; he/she is telling you the diagnosis." Sir William Osler*


- Sudden, maximal at onset, rapid progression, trigger
- Prior similar episodes; resolve, recur
- Variability, fluctuations in sx in one day
- "Panic w/o the panic" (autonomic symptoms)
- Dissociation: derealization, depersonalization
- Medical comorb. (ie, FBM, IBS, CFS, chronic pain/HA)
- Neuro. comorbid.\* (ID, migraine, epilepsy, mild TBI)
- Psych. comorbid.\* (depression, anxiety, PTSD)

*\*also common in many neurological disorders*





# Diagnosis requires positive signs



- FND is a neuropsychiatric disorder in which neurological symptoms are caused by a problem in brain networks
- Diagnosis is based on **POSITIVE ("RULE IN")** signs or semiological features **typical of FND**:

showing **INCONGRUENCE / INCONSISTENCY / REVERSIBILITY** of symptoms

- *No longer a diagnosis of exclusion*
- *No longer need psychological or other stressor preceding to make diagnosis*

# Trick or treat?

Showing patients with functional (psychogenic) motor symptoms their physical signs

Dragging leg gait



Drift w/o pronation



Spasms of face muscles

## Neurological Exam

Hoover sign




'Keep your left heel on the ground – don't let me lift it up'

LEFT hip extension is weak

'Lift up your right leg. Don't let me push it down'

LEFT hip extension returns to NORMAL



Abductor  
sign

# Seizure/Attack

## Seizure ED visits:

- ~ 1% adult
- ~ 2% pediatric

*Pallin et al, J Int Med Emerg 2008*

## Most common causes for TLOC\* (>90%)

- Epilepsy (ES)
- Functional Seizure (aka PNES)
- Vasovagal syncope (VVS)

\*transient loss of consciousness

### Children

Breath-holding spells

Vasovagal syncope

Migraine

Benign paroxysmal vertigo

Staring spells

Tic disorders and stereotypies

Rhythmic movement disorder

Parasomnias

### Adolescents and young adults

Vasovagal syncope

Narcolepsy

Periodic limb movements of sleep

Sleep starts

Paroxysmal dyskinesia

Tic disorders

Hemifacial spasm

Stiff-person syndrome

Migraine

\*

Psychogenic nonepileptic seizures

Hallucinations

### Older adults

Cardiogenic syncope

Transient ischemic attack

Drop attacks

Transient global amnesia

Delirium or toxic-metabolic encephalopathy

Rapid eye movement sleep behavior disorder

# Reliability of Positive Signs for diagnosis

*Adapted from Popkirov et al, Stroke, 2020; Syed et al, Ann Neurol, 2011; Avbersek and Sisodiya, JNNP 2010;*


Clinical Sign	Sensitivity %	Specificity %	Comments
Hoover's	60-100	86-100	In unilateral leg weakness; not SMA, parietal
Hip adductor sign	-	100	Unilateral leg weakness
"Give way" weakness	20-90	95-100	Absence of joint pain
Dragging leg gait	20-100	100	
Drift w/o pronation	47-93	100	Palms up, wait 10 seconds; mild-mod UE weakness
<b>Ictal eye closure</b>	<b>34-88</b>	<b>74-100</b>	<b>Geotropic gaze w/ forced eye opening; blinking after rubbing eyelashes</b>
<b>Ictal weeping</b>	<b>3-7-37</b>	<b>100</b>	<b>Not postictal</b>
<b>Pelvic thrusting</b>	<b>1-44</b>	<b>92-100</b>	<b>Exclude FLS</b>
<b>Side to side head/body</b>	<b>25-63</b>	<b>96-100</b>	<b>Convulsive events only</b>
<b>Asynchronous movements</b>	<b>44-96</b>	<b>93-96</b>	<b>Exclude FLS</b>
<b>Fluctuating course/long duration</b>	<b>47-88</b>	<b>96-100</b>	
Sensory loss- midline split			Not reliable, seen with thalamic stroke

# Video EEG: gold standard for diagnosis

Video of a  
functional/dissociative/non epileptic  
/psychogenic seizure

**Confirm no ictal correlate on EEG**  
**Confirm video is c/w seizure type**


***High specificity/sensitivity positive signs:***  
*Long duration, Fluctuating course,  
asynchronous movements, side-to-side  
head/body movements, closed eyes,  
recall/responsiveness*



## Number Of Smartphone & Mobile Phone Users Worldwide (Billions)

	Number of smartphones	Number of mobile phones
2025*	7.33	7.49
2024*	7.13	7.41
2023*	6.92	7.33
2022*	6.64	7.26
2021	6.37	7.10
2020	6.05	6.95

\*Forecast figures by Ericsson & The Radicati Group



Adapted from Fig. 2, Tatum et al, JAMA Neurology 2020

**If motor signs: ↑ accuracy of smartphone videos and combined with HX/PE → O.R. 5.45**

# Status Epilepticus (SE)

- *A life threatening emergency, if not stopped within one hour can cause lasting brain damage*
- Usual GTCS duration -- 1-2 min
- Prolonged -- >5 min.
- Official -- >30 min.
- Transitional state: seizure clusters



**Functional SE (aka nonepileptic status):** duration not tracked for FS<sup>1</sup>; ~78% pts w/FS report >30 min event and ~39% have "recurrent SE"<sup>2</sup>

Generally, not "life threatening" **however**: risk of iatrogenic harm (intub., procedures)<sup>3,4</sup> and higher rates of mortality<sup>2,5,6</sup>

1. Dworetzky et al, 2010 2. Reuber et al, 2003; 3. Howell et al, 1989; 4. Reuber et al, 2004; 5. Nightscales et al, Neurology 2020; 6. LeZhang et al, JNNP, 2022;


Kapur et al, Established status epilepticus treatment trial(ESETT), *NEJM* 2019;Chamberlain et al, *Lancet* 2020

ESETT trial: 313 cases ( $\geq 8$  y)  
33 (**10.5%**) with final diagnosis  
'nonepileptic event'

48% adverse event  
30% admitted to ICU  
12% intubated!

### Other trials

Navarro et al, <i>Lancet</i> , 2016	4.4%	(6/136)
Aldredge et al, <i>NEJM</i> 2001	5%	(10/205)
Silbergleit et al, <i>NEJM</i> 2012	7%	(63/893)
Chamberlain et al, <i>JAMA</i> 2014	10%	(31/310)



Adapted from Popkirov, FNDS educational webinar



# Distinguishing ES v. FS in the ED

Adapted from Lehn et al, PNES treated as ES in the ED, *Epilepsia* 2021

	Epileptic seizure	Functional seizure (PNES)	Significance, p=
Seizure duration	*	*	0.751, NS
Postictal duration	***	*	<0.001
Lactate level	**		.0026
Previous FND dx	*	***	<0.001
Anxiety	*	**	0.005
Brain surgery or hem.	***	*	<0.001
Intracranial Neoplasm	***	*	.002
Multiple event types	*	***	<0.001

**55.6% szs to ED → ES, 26.5% functional sz; 92% sz to ED received rx for epilepsy**  
 Given timing of blood draw v. baseline, inability to distinguish VVS, focal epilepsy, PNES  
 → prolactin, CPK not very useful (maybe useful in low resource settings)

Fisher, *Neurology Clin Pract* 2016; Chen et al, *Neurology* 2005

# Diagnostic Pitfalls

## Examining a patient with suspected functional seizure and ongoing unresponsiveness

Do NOT attempt or threaten exam maneuvers designed to 'trick' the patient, such as dropping arm over face

Unresponsiveness to noxious stimuli is possible in a deep dissociative state

Appropriate to use typical methods to assess responsiveness (verbal, nail bed compression)

Stereotyped episodes <2 min should be evaluated for epilepsy, even if dissociation or emotional features are prominent

*Adapted w/ permission from a slide by Sarah Finklestein MD; Finklestein, Popkirov, Neurology Clinics, 2023*

# Risks of missing diagnosis of FS

- Risk of ASMs\* and delay to dx/rx<sup>1</sup>
- Risk of rescue procedures (ie, TPA, ICU/intub, catheters/IVs)<sup>2</sup>
- Risk of treating as SE in RCTs, 8% tot, 20% young, 3x>benzos<sup>3</sup>
- Trust eroded in healthcare system and us
- Delay to treatment>3od linked to worse outcomes<sup>4</sup>
- ~4% misdiagnosis rate of other neuro disorder as FND<sup>5</sup>
- **positive signs of FND does not rule out comorbid neuro. disorder** (~ overlap 20%)
  - \*anti-seizure medications

Video of same patient have an epileptic convulsion demonstrating comorbid epilepsy in a patient with frequent functional (nonepileptic) seizures

## Take Homes: Functional Seizures:

- 1) Look for presence of multiple typical semiological features
- 2) Avoid unnecessary escalation of care
- 3) Connect patient to Follow up

# STROKE? DON'T WAIT! B.E. F.A.S.T.

Stroke is an Emergency


- B** Balance Loss
- E** Eyesight Changes
- F** Facial Drooping
- A** Arm Weakness
- S** Slurred Speech
- T** Time to call 9-1-1



# TIME IS BRAIN

NEARLY 2 MILLION BRAIN  
CELLS DIE EACH  
MINUTE A STROKE  
GOES UNTREATED

Learn the signs, Say it's a Stroke, **Save #Precioustime**



  
World Stroke  
Organization

# Symptoms/signs of Acute Stroke

- Sudden arm/ leg /face weakness
  - Sudden sensory disturbance
  - Sudden speech disturbance
  - Sudden vision disturbance- double vision or field cut
  - Sudden difficulty walking or with balance
  - Sudden HA, dizziness, vomiting
- } ~70%
- ~17%

# Reliability of Positive Signs for diagnosis


Adapted from Popkirov et al, Stroke, 2020; Syed et al, Ann Neurol, 2011; Avbersek and Sisodiya, JNNP 2010;

Clinical Sign	Sensitivity %	Specificity %	Comments
Hoover's	60-100	86-100	In unilateral leg weakness; not SMA, parietal
Hip adductor sign	-	100	Unilateral leg weakness
"Give way" weakness	20-90	95-100	Absence of joint pain
Dragging leg gait	20-100	100	
Drift w/o pronation	47-93	100	Palms up, wait 10 seconds; mild-mod UE weakness
Ictal eye closure	34-88	74-100	Geotropic gaze w/ forced eye opening; blinking after rubbing eyelashes
Ictal weeping	3-7-37	100	Not postictal
Pelvic thrusting	1-44	92-100	Exclude FLS
Side to side head/body	25-63	96-100	Convulsive events only
Asynchronous movements	44-96	93-96	Exclude FLS
Fluctuating course/long dur.	47-88	96-100	
<b>Sensory loss- midline split</b>			<b>Not reliable, seen with thalamic stroke</b>

# Stroke Mimics

- Common stroke mimics include **migraine, seizure, FND** (~10%) *Jones 2020*
- Across studies, pts w/ FND tend to be younger (**age < 40 may be a predictor of a stroke mimic**) *Sivakuraman 2016; Chernyshev 2010; Kostulas 2017;*

**Consider pre-test probability of stroke vs other condition (age >50, other RF)**



*Neves Briard et al, J Stroke Cerebrovasc Disorders, 2018*



# Use of tPA in Stroke and Mimics

72582 pts in 485 U.S. Hospitals over 7 yrs using data from "Get with the Guidelines"- Stroke Registry

Year	Stroke rx w/TPA	Stroke mimic	%
2012	6775	134	1.9
2013	8335	195	2.3
2014	9262	268	2.8
2015	10515	373	3.4
2016	12002	695	5.5
2017	12801	740	5.5

*Adapted from Ali-Ahmed et al. 2019 Circ Cardiovasc Qual Outcomes*

# tPA complications in stroke v. mimics

	Stroke Mimics (N=2517)	Ischemic Stroke (N=70,065)	Adjusted OR (95% CI)	P value
Symptomatic ICH	11 (0.4)	2451 (3.5)	0.29 (0.17-0.50)	< 0.001
Serious systemic hemorrhage	1 (0)	516 (0.7)	0.15 (0.03-0.84)	0.03
Other serious complication	26 (1.0)	1938 (2.8)	0.73 (0.51-1.03)	0.08
Any tPA complication	38 (1.5)	4803 (6.9)	0.48 (0.36-0.64)	< 0.001

Adapted from Ali-Ahmed et al *Circulation* 2019

NOTE: Safety data for TNK in stroke mimics is not well-established

Other potential harms: Cost, adverse psychological impact

**→ Probably safe to use tPA in FND if unsure**

# Diagnostic Pitfalls



Over-reliance on mildly positive or single rule-in sign

Overlooking minor concomitant symptoms that are not functional

Allowing demographic or psychological factors to bias diagnosis

# Take homes: Stroke mimics

- 1) Stroke work-up is appropriate for sudden onset neurological symptoms **of unknown etiology**
- 2) **If** diagnosis is **unclear** better to err on side of OVER-treating in patients with **disabling** symptoms
- 3) If FND is high in differential, inform pt that stroke was not found


# Movement Disorders in ED

*Dallochio et al, Neurologic Sciences, 2019*

- 96 consecutive pts w/ **acute** movement d/o presenting to ED
- 46% male (*other studies show 70% female*)
- **74% hyperkinetic**, 26% hypokinetic, 20% mixed

## • Etiology

- 29% Drug induced
- **20% FND** (↓ w/distraction, entrainment) (*other 10%*)
- 15.6% Neurodegenerative
- 11.5% Structural brain lesion
- 24% other (metab., infect., inflam., etc)



# Functional Movement Disorder in ED

- FMD is the **second most common cause** of movement disorder in the ED
- Prevalence ~2-4% adults and children
- 35% unfavorable outcome *Dallochio, et al, 2019*
- Positive features for diagnosis= entrainment (tremor), distractibility, variability

# Positive features of functional movement disorders

Video of functional gait removed

Video of functional tremor removed

Tremor entrainment

Excessively slow, “walking on ice” with knee buckling

# Diagnostic Pitfalls



Bizarre movements do not=FMD

FMD often overlap with other FNS or movement disorder (ie, tremor, gait, tics, myoclonus, parkinsonism)

Caution not to miss: NMS\*, Parkinson's Disease, startle myoclonus in need of urgent work up

*Adapted from slide from Sara Finklestein, w/permission*



# Cauda Equina Syndrome (CES)

- Rare condition in 7/100,000 adults
- Age onset ~ 40 yr , 70% F
- 2/3 normal scans
- **Symptoms**: Pain (back/post. legs), weakness, numbness (inner thighs, buttocks, heels; bowel/bladder/sexual dysfunction)

# Scan Negative “Cauda Equina Syndrome (CES)” v. FND

*Hoeritzauer et al, Neurology 2021*

- Few robust findings on exam; Best may be absent ankle jerks *Hoeritzauer 2021*
- High frequency of positive Hoover sign (associated FND) in CES *Hoeritzauer 2018*
- Over 50% of patients with “CES presentation” have normal scans *Rooney 2009; Bell 2007*
- Post-void residual and anal sphincter tone are NOT good differentiators *Hoeritzauer 2021*
- May be due to a combination of pain, panic/anxiety, medication side effects, **and features of FND**



*Adapted from Slide courtesy of Sara Finklestein, MGH, Boston*

**Pitfall: No historical/exam features eliminate the need for urgent neuro-imaging with suspected CES**

# Management of FND in the ED

## If episode is over

- Documented FND+ typical presentation → connect to follow up, **avoid iatrogenic harm**, no testing, DC home
- Documented FND, new symptoms, remain unbiased and weigh risk/benefit of testing/treatment
- First presentation, test, treatment likely indicated

## If episode is ongoing

- Documented FND + typical presentation → likely need to admit to neurology. Use positive signs to test for FND, avoiding harm (**pt may hear you**)
- Documented FND, new symptoms, do not assume FND, likely need for testing/treatment
- First presentation, test, treat likely indicated

### Take homes:

***If patient has a neurologist or other clinician who knows them, contact them while pt still in ED. Use transparent two-way discussion about possible/likely diagnosis of FND (use protocol) and provide written material or website AND provide appropriate follow up care referral.***

# Challenges: Barriers to Care

## Patient

- Lack acceptance of diagnosis (stigma)
- Non-adherence to treatment
- External locus of control
- Symptom migration: heterogeneous presentations
- Disability benefits
- Social isolation

## Clinician

- Lack of knowledge and understanding of what to do
- Lack of empathy and negative attitudes
- Lack of collaboration/ownership for management
- Concern for malingering or misdiagnosis (liability)
- No follow up provided

## Healthcare System

- Lack of access to care (e.g., mental health services)
- Lack care co-ordination
- Lack communication among healthcare systems and providers

# Treatment considerations in ED

- Avoid iatrogenic harm (ie, invasive procedures, sedation, or **just in case** meds)
- Slow down, **communicate possible or likely FND empathically/effectively**
- **Set expectations about normal or nonspecific findings** if FND high in ddx and why you will be ordering tests in the ED
- Anchor in the here and now with gentle communication (esp. helpful for active “dissociative” seizures: *“we are taking care of you in the ED, the beeping you hear means your VS are ok. It’s a bit cold here, we can get you a blanket. The shaking seems to be easing off and should stop any moment now...”*)


*Silverman et al, FND in the ED, Acad Emerg Med, 2021;*

*Anderson et al, Assessment and Acute Management in the ED, Semin Neurol 2019*

**Pts subjective experience** in ED/ICU: physical restraints, clothing cut off/removed; repeated painful stimuli to test consciousness, insertion of catheters, ICU associated PTSD Reuber et al, J Neurol 2003; Seneveratne et al Epilepsia, 2018

# Multidisciplinary team

**Figure** The Ideal Multidisciplinary Care Team for a Patient With FND




Members of the team interact in a fluid nature as determined by the patient's needs. A neurologist may be the referring clinician or part of the multidisciplinary team.

\*The Team Leader is the individual most engaged with the patient. This could be the PCP, neurologist, or one of the mental health providers.

*Adapted from O'Neal, Baslet, Polich, Raynor, Dworetzky, Functional Neurological Disorder: The Need for a Model of Care, Neurology Clin Practice, April 2021*






Communicating the possibility or likelihood of FND if it is strongly suspected

Anderson et al, Semin Neurology 2019

# Education is critical for everyone

- [www.neurosymptoms.org](http://www.neurosymptoms.org) (UK) (FND); [www.fndsociety.org/fnd-education](http://www.fndsociety.org/fnd-education)
- [www.fndhope.org](http://www.fndhope.org) (US, UK, Australia)(patient support groups)
- [www.nonepilepticseizures.com](http://www.nonepilepticseizures.com) (US – includes info in Spanish)
- [www.nonepilepticattacks.info](http://www.nonepilepticattacks.info) (UK)



- Home
- Symptoms ▾
- Causes ▾
- Treatment ▾
- Stories
- Media ▾
- FAQ
- About
- Fact Sheets


## Functional Neurological Disorder (FND):

FND describes neurological symptoms like limb weakness, tremor, numbness or blackouts, related to the movement and sensation parts of the nervous system.....

- ✓ Caused by a PROBLEM with the FUNCTIONING of the nervous system
- ✓ A “software” issue of the brain, not the hardware (as in stroke or MS)
- ✓ With positive diagnostic features typical of FND
- ✓ Cause day to day difficulties for the person who experiences them

## Functional Neurological Symptoms are:

- More public awareness needed<sup>2</sup>



1. Popkirov et al, *Hiding in Plain Sight: FND in the News*, *J Neuropsych Clin Neurosci* 2019



# Take-Homes: FND in ED

- FND is quite common in the ED
- Diagnose by “positive” features but know the pitfalls\*
- More uncertainty in ED but mention possibility of FND
- Acute Rx, testing: often unavoidable (especially 1st time)
- Set expectations of incidental findings
- Nonjudgmental language(TIC) → *avoid stigma (“software”)*
- If FND strongly suspected, communicate, provide written resources, and indicate that “stroke” was not found
- Refer for follow up, connect with outpt clinician

\*ie, can have comorbid other neurological disorder



**JOIN US**  
Because the FND picture needs you



Membership

[Become a Member](#)

<https://www.fndsociety.org/membership>

**First year free for trainees**

Education/webinars available to members

Verona, Italy June 8-11, 2024 Next International FNDS Meeting